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Abstract 
Atrial fibrillation (AF), the most common and clinically significant heart rhythm disorder, 
is characterized by rapid and irregular electrical activity in the upper chambers resulting in 
abnormal contractions. Radiofrequency (RF) cardiac catheter ablation is a minimally 
invasive curative treatment that aims to electrically correct signal pathways inside the atria 
to restore normal sinus rhythm. Successful catheter ablation requires the complete and 
permanent elimination of arrhythmogenic signals by delivering transmural RF ablation 
lesions contiguously near and around critical cardiac structures. These procedures are 
complex and technically challenging and, even when performed by the most skilled 
physician, nearly half of patients undergo repeat procedures due to incomplete elimination 
of the arrhythmogenic pathways. This thesis aims to incorporate innovative design to 
improve catheter stability and maneuverability through the development of robotic 
platforms that enable precise placement of reproducibly durable ablation lesions. 
The first part of this thesis deals with the challenges to lesion delivery imposed by 
cardiorespiratory motion. One of the main determinants of the delivery of durable and 
transmural RF lesions is the ability to define and maintain a constant contact force between 
the catheter tip electrode and cardiac tissue, which is hampered by the presence of 
cardiorespiratory motion. To address this need, I developed and evaluated a novel catheter 
contact-force control device. The compact electromechanical add-on tool monitors 
catheter-tissue contact force in real-time and simultaneously adjusts the position of a force-
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sensing ablation catheter within a steerable sheath to compensate for the change in contact 
force. In a series of in vitro and in vivo experiments, the contact-force control device 
demonstrated an ability to: a) maintain an average force to within 1 gram of a set level; b) 
reduce contact-force variation to below 5 grams (2-8-fold improvement over manual 
catheter intervention); c) ensure the catheter tip never lost contact with the tissue and never 
approached dangerous force levels; and importantly, d) deliver reproducible RF ablation 
lesions regardless of cardiac tissue motion, which were of the same depth and volume as 
lesions delivered in the absence of tissue motion. 
In the second part of the thesis, I describe a novel steerable sheath and catheter robotic 
navigation system, which incorporates the catheter contact-force controller. The robotic 
platform enables precise and accurate manipulation of a remote conventional steerable 
sheath and permits catheter-tissue contact-force control. The robotic navigation system was 
evaluated in vitro using a phantom that combines stationary and moving targets within an 
in vitro model representing a beating heart. An electrophysiologist used the robotic system 
to remotely navigate the sheath and catheter tip to select targets and compared the accuracy 
of reaching these targets performing the same tasks manually. Robotic intervention resulted 
in significantly higher accuracy and significantly improved the contact-force profile 
between the catheter tip and moving tissue-mimicking material. 
Our studies demonstrate that using available contact-force information within a robotic 
system can ensure precise and accurate placement of reliably transmural RF ablation 
lesions. These robotic systems can be valuable tools used to optimize RF lesion delivery 
techniques and ultimately improve clinical outcomes for AF ablation therapy. 
Keywords 
Catheter Ablation, Catheter Navigation, Radiofrequency Ablation, Contact-Force Control, 
Robotic Catheter Navigation System, Mechatronics, Linear Control Systems 
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Summary for Lay Audience 
Atrial Fibrillation (AF) is a common heart rhythm disorder often treated using catheters 
inserted in the heart to “burn” the tissue responsible for the arrhythmia (i.e. to make 
lesions). Radiofrequency (RF) catheter ablation strategies to treat AF are complex, 
technically challenging, and require a high degree of skill and physical effort. Furthermore, 
the motion of the heart as it beats and the patient breathes can affect the contact the catheter 
tip makes with the heart during the therapy delivery. This makes it very difficult for the 
physician to deliver lesions effectively. Because of these problems, it is not uncommon 
that lesions are delivered inadequately, leaving untreated tissue that can result in the 
recurrence of AF symptoms. Currently, nearly half of all patients return for a second 
procedure. 
To avoid repeat procedures, ablation lesions must be precisely placed in specific locations 
within the heart chamber – lesions must be adjacent to one another and share a common 
border. Additionally, these lesions must be reliably durable and cover the entire heart-wall 
thickness. One key element that governs lesion production is stable contact force between 
the catheter tip and heart tissue. With the advent of force-sensing ablation catheters, 
physicians can monitor the amount of force the catheter makes with the tissue in real-time. 
However, physicians are limited in controlling the force and have no way to improve force 
stability and keep it constant during RF delivery. 
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My thesis describes the development and evaluation of two novel robotic technologies 
designed to address these problems. Specifically, I introduce the Catheter Contact-Force 
Controller (CFC) and the Steerable Sheath and Catheter Robotic Navigation System (SSC-
RNS). These platforms are used in conjunction with standard, commercially available 
ablation instruments to provide automated catheter-tissue contact-force control and precise 
remote catheter navigation. I discuss their design and development as well as how these 
systems performed on a lab-bench and in pre-clinical studies. I show that the CFC is 
effective in stabilizing the force during lesion delivery, resulting in uniform lesions despite 
the presence of motion. Use of the SSC-RNS led to improved location accuracy of catheter 
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1 Introduction and Background 
This introductory section provides a brief overview of relevant background information 
relating to the research described in the following chapters. This section also describes 
atrial fibrillation, cardiac catheter ablation, the current state-of-the-art tools and 
technologies used in the clinic. The proposed robotic systems designed to address the 
current challenges associated with current catheter ablation strategies are also discussed. 
1.1 Atrial Fibrillation 
Atrial fibrillation (AF), the most common and clinically significant cardiac arrhythmia, is 
a heart rhythm disorder characterized by chaotic electrical activity in the upper chambers 
(atria) of the heart. False electrical signals are generated from different parts within the 
atria causing abnormal contractions, resulting in a rapid and irregular heartbeat that can 
occur in episodes or last permanently [1]. During an AF episode, a surface 
electrocardiogram (ECG) will typically illustrate an irregular R-R interval and the absence 
of a distinct P-wave, as illustrated in Figure 1.1 [2, 3]. AF is typically categorized as either: 
paroxysmal defined as recurrent that resolves within seven days; persistent defined as 
continuous AF that is sustained beyond seven days; long-standing persistent defined by 
continuous AF sustained beyond 12 months; or, permanent if treatment has failed or has 
been discontinued [4]. 
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Figure 1.1. In comparison to a normal sinus rhythm A, a surface ECG 
of AF B will illustrate an irregular R-R interval and the absence of a 
distinct P-wave (red). 
In North America, Europe, and Asia, the current estimated prevalence of AF is between 
1% to 4% [5, 6]. In the ATRIA study, within a large and ethnically diverse population, they 
found that 1% of all adults were diagnosed with AF, and nearly 4% of individuals 60 years 
and older and 9% of individuals 80 years or older being diagnosed [7]. In addition to 
increasing age, the probability of developing AF is also influenced by inherited and 
acquired risk factors [8, 9]. Current estimates reveal that globally, 33 million people have 
some form of AF [10]. Reflecting the increasing proportions of the elderly, this number is 
projected to increase 2-4-fold by 2050 [7, 11, 12].  
The healthcare burden associated with AF has increased and is expected to continue rising. 
In the United States, AF accounts for more than 479,000 hospitalizations yearly and has 
contributed to more than 130,000 deaths [13]. AF has been reported to increase the annual 
healthcare cost by USD 8,705 per patient resulting in between USD 6B and USD 26B per 
year in additional US healthcare costs [14]. In Canada, each AF patient costs CAD 6,718 
attributing to CAD 815M [15]. The reported costs are based on databases collected between 
2011 and 2013 and likely have increased significantly since its reporting. AF already has 
demonstrated tremendous implications on the global economy and public health [16] and 
this situation is rapidly becoming worse. 
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Clinically, the most critical complication associated with AF lies in the risk of cardiac 
thrombus formation. Because of this, AF is a strong independent risk factor for embolic 
strokes [17-19]. On average, AF increases the risk of stroke 5-fold [20], and strokes of AF-
related etiology are twice as likely to be fatal in comparison to non-AF related strokes [21]. 
Estimates show that AF causes one-third of all strokes after the age of 60. In addition to 
age above 60, other significant risk factors of AF-related stroke include female sex, prior 
stroke, congestive heart failure, diabetes, and hypertension [22, 23]. 
The root causes of AF are unclear, but many concepts explaining its mechanism have been 
speculated: multiple re-entrant wavelets, rapidly discharging automatic foci, and a single 
re-entrant circuit with fibrillatory conduction [1]. Substantial progress has been made in 
understanding and defining the mechanisms underlying AF initiation and progression [24, 
25]. It was recognized that AF is triggered or maintained by rapidly firing foci entering the 
left atrium (LA) originating from the cardiac muscle cells extending within the walls of the 
pulmonary veins (PVs). To this end, AF can be treated permanently with local catheter 
ablation near the PVs [26, 27]. 
1.2 Catheter Ablation 
Cardiac catheter ablation is a minimally invasive curative treatment that aims to isolate the 
PVs from the atria electrically. Radiofrequency (RF) energy is delivered to cardiac tissue 
using an electrophysiology ablation catheter, resulting in the production of an ablation 
lesion. 
A catheter ablation procedure begins with a small incision made in the groin, allowing a 
guidewire to be advanced to the right side of the heart via the femoral vein. A trans-septal 
puncture, guided by fluoroscopy and ultrasound, is performed through the fossa ovalis to 
gain access to the left atrium. An RF ablation catheter can then be introduced and 
manipulated within the cardiac chamber (Figure 1.2). Using a variety of modalities and 
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catheter navigation technologies (such as fluoroscopy and electromagnetic guidance), an 
electrophysiologist (EP) manipulates the catheter to specific targets in the LA and delivers 
numerous contiguous RF “applications” into the tissue. 
 
Figure 1.2. The catheter is introduced into the left femoral vein and fed 
up to the right atrium (RA) via the inferior vena cava (IVC). A trans-
septal puncture through the fossa ovalis (FO) allows the catheter to be 
introduced into the left atrium (LA) and deliver RF ablation lesions near 
the pulmonary veins (PV). The right and left ventricles (RV and LV, 
respectively) are not illustrated. This line drawing was adapted from 
Calkins et al. [1]. 
An ablation catheter is a long and flexible medical device consisting of a proximal handle, 
which allows the EP to insert, withdraw, and rotate an RF electrode tip within the patient’s 
heart. A deflection mechanism on the handle applies tension to pull-wires within the 
catheter lumen resulting in the deflection (or bending) of the catheter tip along one, two, 
or four orthogonal angles, as illustrated in Figure 1.3. 
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Figure 1.3. An ablation catheter consists of a proximal handle connected 
to a long and flexible tube, which houses various lumens, electrical 
wires, and pull-wires. An operator can insert, withdraw, and rotate an RF 
electrode (located at the very tip of the catheter) to make contact with 
cardiac tissue and deliver RF energy. A uni- or bi-directional mechanism 
on the handle deflects the distal tip (shown in red). The catheter tip 
incorporates electromagnetic location sensors, and electrodes used for 
delivering RF energy, recording intracardiac ECG, and cardiac pacing. 
Ablation catheters also include an irrigation line, which allows saline to 
be pumped continuously to cool the electrode during RF delivery. 
Precisely placing transmural (across the thickness of the tissue) ablations lesions near the 
PVs blocks the electrical signals from disturbing the normal sinus rhythm of the heart. A 
common strategy employed in AF ablation is to deliver contiguous lesions encircling the 
ostia of the PVs. This procedure is known as pulmonary vein isolation (PVI), whose goal 
is to electrically isolate the left and right pairs of PVs from the LA [1]. The circumferential 
ablation lesions performed during PVI can be followed with additional ablation sets, as 
illustrated in Figure 1.4. 
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Figure 1.4. Line illustration represents the LA from the posterior 
perspective. PVI requires the precise placement of contiguous 
circumferential ablation lesions encircling the right and left PV pairs 
(red). The left PV pair includes left superior and inferior pulmonary 
veins (LSPV and LIPV, respectively), while the right PV pair consists of 
the right superior and inferior pulmonary veins (RSPV and RPIV, 
respectively). Other standard ablation lines include: a roof line 
connecting the left and right circumferential lesions (purple) and a 
corresponding inferior ablation line (yellow) resulting in a complete 
isolation the posterior wall; linear lesions between each PV pair (blue); 
and a mitral isthmus ablation line connect the left PV pair with the mitral 
valve (green). This line drawing was adapted from Calkins et al. [1]. 
To facilitate catheter navigation, modern catheter labs are equipped with electro-
anatomical mapping (EAM) systems, which have led to a paradigm shift in treating patients 
with cardiac arrhythmia. EAM systems are used to define the mechanisms of arrhythmias, 
design ablation strategies, guide ablations, and improve safety by identifying critical 
cardiac structures. While manipulating the catheter in the cardiac chamber, its position and 
orientation are monitored by a low-field magnetic generator, which locates electromagnetic 
sensors incorporated within the catheter tip with sub-millimetre accuracy (Figure 1.5). In 
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addition to the primary ablation catheter, EPs can use a mapping catheter (taking the form 
of a lasso or paintbrush) to capture the 3D anatomical structure of the heart and determine 
the ECG at any mapped point in the cardiac chamber. By gating the acquisition of points 
to the cardiac electrical activity, points that represent both location and its corresponding 
electrical activity are acquired. A 3D representation is constructed and displayed to the EP. 
EAM systems allow for further understanding of arrhythmias and increase the safety, 
efficacy, and efficiency of catheter ablation, which has helped decrease procedural 
complexity and procedure time [28, 29]. 
Despite decades of intensive research and innovation, resulting in an arsenal of tools 
available to the EP, long-term results of catheter ablation demonstrate a high rate of 
recurrence following the first procedure. Early recurrences of AF, occurring after a 3-
month blanking period post-ablation, have been reported in up to 50% to 70% of patients 
[30-33]. The low efficacy rate of first-procedure clinical success is likely due to the 
inability to create transmural and durable lesions in a contiguous fashion, ultimately 
resulting in the reconnection of the PVs with the LA. In these cases, a repeat procedure is 
performed in an attempt to re-isolate the PVs. With multiple procedures, the long-term 
success rate can be improved to 80% overall. It has been reported that, on average, each 
AF patient undergoes 1.5 ablation treatment to restore normal sinus rhythm [33]. 




Figure 1.5. A typical modern EP lab is equipped with an EAM system 
which captures the location of the catheter tip using an electromagnetic 
field generator located under the chest of the patient A. Other equipment 
includes an RF generator and irrigation pump, a system for recording 
ECG signals, and fluoroscopic x-ray system (not shown). The EAM 
system is on display in front of the EP B. The EP can track the position 
of the tip of the ablation catheter (green arrow) in relation to a map of 
the patient’s cardiac chamber and monitor the real-time catheter-tissue 
contact force (green square) between the tip and moving cardiac tissue. 
An additional mapping catheter (orange arrow), in the form of a 
paintbrush, is used to collect intracardiac ECG. The EAM system is also 
used to plan and guide ablation lines (white arrow) and track the 
locations of previously delivered lesions (red arrows). 
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Non-ablative strategies to treat AF includes the use of antiarrhythmic drugs. Three 
prospective randomized clinical trials have examined the efficacy of ablation as the first 
treatment versus antiarrhythmics [34-36]. A meta-analysis summarizing those trials [37], 
concluded that ablation was associated with significantly higher freedom from long-term 
AF recurrence in comparison to the pharmacological counterpart and provided the evidence 
to support AF ablation as first-in-line therapy. In the recent CABANA trial [38], involving 
over 2200 patients, they also demonstrated an association with lower AF recurrence rate 
using catheter ablation over drug therapy. The Cox-Maze procedure, an open-heart surgical 
approach to permanently treat AF, requires a cardiac surgeon to place a series of epicardial 
incisions (in a similar fashion to RF ablation) to interrupt the abnormal AF signals 
permanently. This procedure is routinely practiced and recommended at the time of 
simultaneous mitral and aortic valve operations and coronary artery bypass grafting. 
Although this thesis focuses on AF, it is important to recognize that RF catheter ablation 
is used to treat other forms of supraventricular arrhythmias, such as atrial flutter and 
atrioventricular nodal re-entrant tachycardia, which require ablation in the RA, as well as 
ventricular tachycardia, which requires ablation in the LV. 
1.2.1 Biophysics of Radiofrequency Lesion Formation 
Radiofrequency energy is created by using alternating electrical current to generate an 
ablation lesion by electrical heating the cardiac tissue. Thermal energy deposited into the 
tissue is used to destroy the arrhythmogenic substrates by heating them to a lethal 
temperature; the 50°C isotherm determines the boundary of the lesion where tissue injury 
is irreversible. As electrical current passes through the tissue, the voltage drops, and heat 
is produced; this is called resistive heating. RF current is primarily delivered in a unipolar 
fashion with completion of the electrical circuit through an indifferent electrode placed on 
the skin (Figure 1.6). Typically, 500 to 750 kHz is used for efficient tissue heating while 
avoiding stimulating cardiac muscle and nerves. 
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Figure 1.6. Circuit path for RF catheter ablation. Blood pool resistance 
is about half of that than cardiac tissue. Out of the 50 W of energy 
delivered from the catheter, only 5 W is deposited in the tissue because 
of power loss caused by the lower resistance (and impedance) of the 
blood pool. The amount of power delivered into the tissue is based on 
the amount of electrode surface in contact with the tissue, which is a 
function of electrode size, the orientation catheter in relation to the tissue 
surface, and the amount of electrode-tissue contact force. This 
illustration has been adapted from Huang & Miller [39]. 
Resistive heating decreases proportionally with the distance from the electrode to the fourth 
power. As a result, only a narrow rim of tissue in contact with the catheter electrode 
(approximately 2-3 mm) is heated. The majority of lesion production (and deep tissue 
heating) is a result of passive thermal conduction (Figure 1.7). Tissue temperature at any 
given distance from the electrode increases exponentially with proximity to the electrode. 
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The formation of coagulum at the electrode-tissue interface occurs when the temperatures 
exceed 100°C. As the blood and tissue in contact with the electrode begin to boil, denatured 
proteins stick to the surface of the electrode. Because coagulum electrically insulates the 
surface of the electrode, a concentration of power occurs over a reduced surface area. This 
positive feedback loop can cause a complete encasement of the electrode with coagulum 
within seconds. Modern RF generators use sharp increases in impedance, associated with 
coagulum encasement, to shut off RF energy. The formation of coagulum can cause micro 
embolisms, which have been shown to cause cerebral embolic lesions [40-42].  
When deep tissue layers exceed 100°C, intramuscular water begins to boil and cause a 
sudden buildup of steam. High pressure is released, which can be heard or felt as a steam-
pop [43]. Damage caused by steam pops ranges from superficial endocardial craters to full-
thickness myocardial tears resulting in cardiac perforation and tamponade.  
Active electrode irrigation is used to mitigate the effects of the electrode and tissue 
overheating. Continuous saline irrigation bathes and cools the RF electrode and superficial 
tissue layers (Figure 1.7), thereby allowing for longer RF application times and optimal 
RF power delivery, resulting in larger lesions. Modern catheters are designed with either 
closed-loop or open irrigation systems (catheter photographed in Figure 1.3 uses an open 
system). Illustrated in Figure 1.5A, an irrigation pump – triggered with the RF generator 
– continuously pumps saline through to the electrode through the irrigation port of the 
catheter. 
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Figure 1.7. Drawing of RF catheter ablation on tissue demonstrating 
resistive and conductive heating. Continuous irrigation cools the 
electrode and tissue surface, allowing larger lesions to be formed by 
prolonging ablation time. Additional heat is lost passively through the 
blood pool (convective) and cardiac tissue (perfusive). This illustration 
has been adapted from Huang & Miller [39]. 
Several factors influence ablation lesion size includes: RF power, duration of RF energy 
delivery, electrode-tissue contact force, tissue composition, electrode temperature, peak 
tissue temperature, convective cooling, electrode size, ablation circuit impedance, 
electrode orientation, electrode geometry, electrode material, and characteristics of RF 
power. Electrode-tissue contact force is a novel concept and has emerged as a critical factor 
in RF catheter ablation – this thesis heavily focuses on this concept. For this reason, it is 
essential that thorough comprehension of catheter-tissue contact force is acquired. 
1.2.2 Role of Contact Force in RF Catheter Ablation 
Successful catheter ablation requires the complete and permanent elimination of 
arrhythmogenic substrates by delivering ablation lesions that are reliably transmural 
without collateral injury to other cardiac structures. RF energy creates resistive heating of 
the tissue that is in direct contact with the electrode tip, and therefore, sufficient catheter-
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tissue contact is essential [44]. A major determinant of lesion size and depth is the amount 
of contact force (CF) between the catheter tip electrode and moving tissue. Greater CF 
increases lesion size by improving electrical coupling between the electrode and tissue. 
This increases the electrode surface area in contact with the tissue and reduces the shunting 
of current to the blood pool. Additionally, greater CF prevents the electrode from sliding 
with cardiac motion. To this end, manufacturers have developed ablation catheters with a 
force sensor integrated into the distal tip to measure real-time catheter-tissue CF during 
mapping and RF ablation. These force-sensing ablation catheters detect forces in 3D with 
high resolution (< 1 gram [g]) and display it visually on the EAM system (Figure 1.5). A 
large-scale clinical study has shown that force-sensing ablation catheters reduce gaps 
between adjacent lesions, steam pops, cardiac perforation, thrombus formation, and 
fluoroscopy time, while at the same time improving lesion formation and reducing AF 
recurrence rates [45]. 
Ablations lesions delivered with low levels of CF are superficial, increase the risk of 
intermittent contact (occasional complete loss of contact) is correlated with sites of PV 
reconnection [46-49]. In contrast, excessive CF is associated with deep tissue heating, 
increase the risk of steam-pop, perforation, thrombus formation, and collateral tissue 
damage to structures outside the heart, such as esophageal, pulmonary and phrenic nerve 
injury [50-56].  
In an attempt to optimize durable PVI, clinical studies have provided CF guidelines. 
Notably, the EFFICAS II study (investigating 24 patients) demonstrated isolation of the 
PV using a CF target of 20 g, ranging between 10 g and 30 g, with a minimum Force-Time 
Integral (FTI, defined as the under the contact-force curve with respect to time [44]) of 400 
grams-seconds (gs) [57]. In addition to the overall average CF, CF variability (or stability) 
is thought to be an essential parameter in determining RF lesion formation [44]. The 
SMART-AF trial, investigating 172 patients, showed an increase in clinical success when 
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more time was spent within a pre-defined CF range (i.e., reduced CF variability) [58]. 
Specifically, investigators who stayed within a selected CF range more than 80% of the 
time during RF applications were more than four times more likely to have clinical success 
in comparison to those who did not. The study concluded that there is a non-linear 
relationship between CF and clinical success and that CF stability with sufficient average 
CF, rather than merely achieving higher average CF, is the key to creating durable ablation 
lesions. Contact quality (which includes catheter stability, cardiorespiratory motion and 
catheter drift), rather than absolute CF alone, has emerged as a critical element that governs 
lesion size and ablation outcomes. A meta-analysis summarizing all randomized controlled 
trials of CF ablation in AF (TOCATTA [59], EFFICAS I [45], EFFICAS II [57], SMART-
AF [58], and TOCCASTAR [60]) reports ideal clinical outcomes appear when modest CF 
is reached while consistently staying within the CF target range during ablation [61]. 
Smaller clinical studies have looked at further quantifying CF variability to provide more 
context in lesion production and clinical success. Ullah et al. [62] demonstrated that lesions 
delivered with variability over 5 g are associated with a lower impedance drop (a surrogate 
for poor lesion production), despite delivering the same FTI. Additionally, Makimoto et al. 
[63], demonstrated that the relationship between the average and standard deviation of CF 
(relative standard deviation [RSD] or the coefficient of variation) correlates with PV 
reconnection. They show that ablation segments along the circumferential ablation lines 
delivered with lower average force and high variability are prone to form reconnection 
gaps. For instance, in the anterior portions of the left PVs, where the most frequent 
reconnection gaps are found, not only was the average CF low, but the variability was also 
very high (Figure 1.8). Additionally, although the roof and posterior segments of the right 
PVs have a typically adequate average CF, they have a high CF variability resulting in a 
high RSD – this may be the reason why reconnection gaps are found in these locations [64, 
65]. This notion reinforced by Kumar et al. [66], where they demonstrated that the CF 
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variability was higher at the sites of reconnection than at non-reconnected sites. RF 
applications delivered with high CF variability result in lesions 30%-60% smaller in 
volume compared to constant CF, despite being delivered with the same power, duration, 
and maximum force [44]. The larger the dynamic range of CF, the less likely the lesion 
would reach an appropriate FTI and the longer the required duration of RF application. All 
these data suggest that CF variability, in addition to average CF, plays a vital role in durable 
ablation production. 
In clinical practice, it is virtually impossible to reliably maintain stable CF between the 
catheter tip and moving tissue. Thousands of RF applications across hundreds of patients 
have been analyzed. In one study (+1600 RF applications across 22 patients), the average 
force among the interquartile range is between 6 g and 40 g [67]. In another study (+1400 
RF applications across 20 patients performed by two operators), showed that one-in-five 
RF applications were delivered sub-optimally with less than 5 g on average, despite 
attempts to “optimize” CF [68]. In a final study (+900 RF application across 20 patients), 
19% of RF applications were delivered with a variability of less than 10 g, while the rest 
remained highly variable greater than 20 g, despite further attempts to optimize CF [69]. 
Furthermore, average CF and variability also significantly differ depending on whether or 
not the patient is in sinus rhythm as well as anatomical regions within the LA [63, 67, 68, 
70]. 




Figure 1.8. Maps of average CF A and relative standard deviation 
(RSD=[SD/Mean]∗100%) B acquired in partial segments along 
circumferential ablation lines during PVI. Areas of RSD over 40% are 
typically associated with regional locations where reconnection gaps 
occur. RSD regions less than 30% are generally non-problematic. 
Average CF was higher in the roof and posterior segments of LSPV and 
RSPV and lower in the anterior portion of the left PVs. Furthermore, roof 
and posterior segments of the RIPV and the anterior segment LSPV, 
RSD was significantly higher as compared to the other sections, 
implying a higher risk of reconnection. Figure created based on data 
from Makimoto et al. [63]. 
Systolic-diastolic cardiac motion and respiration are the primary contributors to variability 
in CF [66, 67, 69]. Given the need to minimize tissue movement to improve CF stability, 
techniques have been introduced clinically, which aim to decrease the amplitude of cardiac 
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and respiratory motion by increasing their corresponding frequencies. For example, rapid 
atrial pacing (increasing heart to over 120 BPM) improves catheter stability in the presence 
of cardiac motion [71]. However, the improvement in CF variability is minimal (less than 
1 g) and is dependent on regional lesion location within the LA. Furthermore, patients can 
be sensitive to prolonged periods of rapid atrial pacing resulting in a quick drop in blood 
pressure. High-frequency jet ventilation (HFJV) which increases the ventilation rate to 100 
cycles/minute, or inducing patient apnea (breath-hold) can be used to eliminate CF 
variability caused by respiratory motion [66, 72, 73]. HFJV may not be suitable for many 
patients due to adverse effects [74, 75]. Importantly, HFJV and apnea induction requires 
general anesthesia, which relies on the availability of an anesthesiologist and the protocol 
of the center where the procedure is performed. Problems associated with general 
anesthesia include increased risk of atrial-esophageal fistula, although this is extremely 
rare [76]. Among the Heart Rhythm Society and European Heart Rhythm Association 
expert consensus, approximately 70% routinely employ general anesthesia (and apnea 
induction) for AF cases, and only 8% reported the use of HFJV [1]. 
As RF catheter ablation extends to more and less experienced operators, clinical success 
will continue to vary centre-to-centre. This is further exacerbated by the variety of tools 
and technologies at the electrophysiologist’s disposal. With limited methods to mitigate 
the effect of excessive cardiorespiratory or patient motion, it is virtually impossible for EPs 
to reliably meet any CF guidelines outlined by these reported clinical studies. It is evident 
that there is a clear need for new technology to control catheter-tissue CF to optimize point-
by-point RF ablation technique. Controlling for catheter-tissue CF and its effect in lesion 
production is a principal component of this thesis. 
1.3 State-of-the-Art Commercial Technology 
This section presents tools and technologies routinely employed for AF ablation 
procedures. Emerging technologies, tools, and approaches such as cryoablation, laser and 
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ultrasound ablation, balloon-based single-shot catheters, and electroporation are not 
addressed. This section is limited to existing commercial technologies – relevant to the 
context of this thesis – utilized in point-by-point RF catheter ablation strategies. 
1.3.1 Electro-Anatomical Mapping Systems 
Modern EP labs incorporate an EAM system, which is used to track the position of an 
ablation catheter tip in relationship to an electro-anatomical map of the patient’s cardiac 
chamber. EAM systems record and display electrical activation related to the anatomical 
location of the recorded sites, which help diagnose and guide ablation procedures. 
Innovative catheter technologies, specifically robotic technologies, are typically 
incorporated with EAM systems. For this reason, it is essential that a basic comprehension 
of EAM systems is acquired. To this end, three commercially available EAM systems 
routinely used in the clinic are described in this section. 
1.3.1.1 CARTO® 3 Catheter Mapping System 
The CARTO® 3 System (Biosense Webster, Irvine, CA) [77] is an advanced mapping 
technology that utilizes electromagnetic tracking to create real-time 3D maps of a patient’s 
cardiac structures. The system is designed to help electrophysiologists navigate the heart 
by generating an accurate 3D map, as well as track the location and orientation of catheters 
in the heart during ablation therapy. 
CARTO® is based on three foundations: ECG, location, and mapping. The ECG subsystem 
receives body surface and intracardiac ECG, which are filtered, presented and recorded 
with CARTO®. To ensure that catheter tracking is not influenced by human conductivity, 
CARTO® uses an electromagnetic field generator, consisting of three magnetic coils, to 
track the electromagnetic sensors on the tip of the catheter (Figure 1.9), as well as locations 
from six patches attached to the patient (three on the back and three on the chest). Lastly, 
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CARTO® mapping technology is used to build maps of the heart chambers by combining 
the precise location and ECG data.  
The base CARTO® system can be equipped with optional software modules for differing 
clinical needs. Some of these modules include force-sensing ablation catheter 
(SMARTTOUCH™ Module); computed tomography (CT) and magnetic resonance 
imaging (MRI) image integration and registration (CARTOMERGE®); and remote 
catheter magnetic navigation (RMT Module) [77]. 
 
Figure 1.9 Illustration demonstrating electromagnetic tracking of the 
catheter tip. Three coils, suspended under the patient’s chests beneath the 
EP table, emit a low-level magnetic field represented by colour-coded 
hemispheres. A 6 degree-of-freedom electromagnetic sensor within the 
tap of the mapping or ablation catheter, measures the field strength from 
each coil. The relative position to each coil is then triangulated to 
determine the relative position and orientation of the catheter tip. 
Illustration adapted from Bhakta et al. [78]. 
1.3.1.2 EnSite Precision™ Cardiac Mapping System 
The EnSite Precision™ Cardiac Mapping System (Abbott Laboratories, Minneapolis, MN) 
[79] is a 3D cardiac mapping system with features similar to that of CARTO® such as 
catheter tracking, mapping and recording ECG with expanded optional software modules. 
The distinguishing technical difference between the two systems is that the EnSite 
Precision™ system combines impedance-based and electromagnetic-based tracking 
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technologies to enable navigation and accurate tracking of both conventional catheters 
(open to 3rd-party manufacturers) and sensor-enabled catheters. EnSite Precision™ is an 
open-platform system that compliments both tracking technologies. 
Over the past two decades, the CARTO® and EnSite Precision™ have dominated this 
market and have been used in thousands of clinical studies worldwide, demonstrating its 
efficacy in treating several forms of cardiac arrhythmia. PVI procedures guided by either 
of these systems have been shown to yield similar clinical outcome [80]. The widespread 
use of these systems is associated with higher success rates, shorter fluoroscopy and 
procedure times, and accurate visualization of the cardiac chambers. 
1.3.1.3 RHYTHMIA HDx™ Mapping System 
A third system – the RHYTHMIA HDx™ Mapping System (Boston Scientific, 
Marlborough, MA) [81] – is similar to the EnSite Precision™ system whereby it utilizes 
both electromagnetic-based and impedance-based catheter tracking technology. Although 
this system holds a smaller percentage of the market, in comparison to CARTO® and 
EnSite Precision™, it does stand out by providing a unique mapping catheter. The 
INTELLAMAP ORION™ mapping catheter is capable of generating a rapid ultra-high-
density ECG map of the patient’s cardiac chamber [81]. This unique catheter has been 
shown to improve long-term success in comparison to procedures guided by CARTO® or 
EnSite Precision™ [82]. The RHYTHMIA HDx™ and INTELLAMAP ORION™ are 
effective for treating various forms of cardiac arrhythmia, as demonstrated in several pre-
clinical and clinical studies [83-92].  
Unfortunately, unlike their competitors, to date, Boston Scientific does not provide an 
ablation catheter capable of detecting real-time contact force measurements. Several 
patents granted to Boston Scientific in 2017 describe a catheter capable of detecting 
catheter-tissue CF [93-96], suggesting that such a catheter will soon be available. 
21 Introduction and Background 
 
1.3.2 Force-Sensing Ablation Catheters 
1.3.2.1 THERMOCOOL® SMARTTOUCH™ Catheter 
The THERMOCOOL® SMARTTOUCH™ Catheter (Biosense Webster, Irvine, CA) [77] 
is an ablation catheter that measures the CF between the catheter tip and moving tissue. A 
precision spring located just proximal to the ablation tip electrode is affixed to an 
electromagnetic transmitter coil (distal to the spring), which emits a magnetic field. Three 
additional electromagnetic coils (positioned circumferential proximal to the spring) 
generate an electrical current proportional to the micro-deflection caused by an applied 
force to the catheter tip (Figure 1.10). A proprietary algorithm computes a 3D force vector 
at approximately 20 Hz and displays both magnitude and direction continuously on the 
CARTO® 3 System [97]. 
 
Figure 1.10. Photograph of THERMOCOOL® SMARTTOUCH™ force-
sensing ablation catheter tip A. A precision spring is affixed to a 
transmitter coil emits a magnetic field. Three electromagnetic receiver 
coils generate an electrical current proportional to the deflection caused 
by force applied to the tip (blue arrow) B. 
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The THERMOCOOL® SMARTTOUCH™ catheter also comprises standard 
electrophysiology catheter features, such as an RF electrode tip, location sensors, ECG 
mapping and pacing as well as a saline irrigation port. The THERMOCOOL® 
SMARTTOUCH™ catheter was the first catheter with force-sensing technology to be 
approved by the U.S Food and Drug Administration (FDA) for use in cardiac ablation 
therapy. 
1.3.2.2 QDOT MICRO™ Catheter 
The QDOT MICRO™ Catheter (Biosense Webster, Irvine, CA) [77] is the next generation 
force-sensing ablation catheter developed by Biosense Webster (Figure 1.11). In addition 
to force-sensing technology, the new catheter incorporates three micro-electrodes 
embedded at the distal circumference within the standard distal RF electrode. Each 
acquired point within CARTO® records four intracardiac electrograms: one from the 
standard electrodes and three from the micro-electrodes. This design allows for recording 
an ECG from a small tissue area, which has been shown to improve mapping resolution 
and diagnosis of electrograms while limiting the need for and cost associated with the use 
of separate mapping catheters [98]. The QDOT MICRO™ also incorporates six 
thermocouple temperature sensors (three proximal and three distal) embedded 75 
micrometres underneath the surface of the RF electrode’s metal shell. The symmetrical 
distribution of thermocouples is optimized to monitor temperature at all orientations the 
catheter makes to the tissue (defined as catheter-tissue incidence angle), resulting in more 
accurate temperature readings from parts of the RF electrode in contact with the tissue. In 
contrast, conventional catheters average the tip temperature, which is diluted by the cooler 
parts of the tip that are not touching the tissue and the effects of blood and irrigation. 
The incorporation of accurate local temperature monitoring allows for safe delivery of an 
emerging RF technique, which uses high-power RF ablation. The proposed benefit of this 
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approach is to reduce the effects of lesion-to-lesion variability that result in reconnection 
gaps. Several pre-clinical studies have shown to improve linear continuity, the delivery of 
transmural ablation lesions, shorter ablation time, feasibility and safety. [99-101] 
 
Figure 1.11. Line illustration of the tip of the QDOT MICRO™. The 
novel force-sensing ablation catheter incorporates (1) six thermocouple 
temperature sensors underneath the surface of the RF electrode for 
improved temperature monitoring of the tissue surface; (2) three micro-
electrodes for high-resolution intracardiac EC mapping; and (3) an 
improved tip irrigation system. 
1.3.2.3 TactiCath™ Quartz Contact Force Ablation Catheter 
The TactiCath™ Quartz Contact Force Ablation Catheter (Abbott Laboratories, 
Minneapolis, MN) [79] contains a force sensor consisting of a deformable body and three 
optical fibres [102]. Infrared light (emitted through the proximal end of the optical fibres) 
travels through the catheter towards a cavity within the catheter tip (Figure 1.12). The 
incoming light is bounced back and forth between two parallel reflective mirrors within the 
cavity, resulting in reflected light with different wavelengths creating interference patterns. 
When force is applied, the cavity length changes (on the order of nanometers) resulting in 
a proportional change in the interference pattern. The reflected light is returned through to 
the proximal handle by three optical fibres symmetrically distributed around the cavity. A 
CF vector (magnitude and direction) is calculated and displayed on the EnSite Precision™ 
Cardiac Mapping System (Abbott Laboratories, Minneapolis, MN) [46]. 
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Figure 1.12. Photograph of TactiCath™ force-sensing ablation catheter 
tip A. The force sensor consists of a deformable body and three optical 
fibres. When force is applied to the tip (blue arrow), a cavity within the 
deformable body reflects infrared light (indicated in red) with an 
interference pattern proportional to the change in force B. 
The accuracy and precision of TactiCath™, as well as its safety and effectiveness in ablation 
procedures, have been investigated in several studies [45, 46, 57, 103]. The TactiCath™ 
was shown to have improved accuracy over the THERMOCOOL® SMARTTOUCH™ 
catheter, specifically while the catheter is in an orientation parallel to the tissue (i.e. 
delivering “linear” lesions) [104]. 
1.3.3 Steerable Sheaths 
A steerable guiding sheath is a widely used tool available to the EP during ablation 
procedures. Used in conjunction with ablation catheter, steerable sheaths have been shown 
to improve maneuverability and stability of the ablation catheter, as well as enhance contact 
between the catheter tip and cardiac tissue during lesion production [105-109]. 
Incorporating a steerable sheath has also been shown to increase first-procedure clinical 
success rates over its non-steerable counterpart [110]. 
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The Agilis™ NxT Steerable Introducer (Abbott Laboratories, Minneapolis, MN) [79] is the 
world’s most commonly used steerable sheath. The handle of the Agilis™ consists of a 
hemostatic seal and side-port irrigation line proximal to the handle. An ablation catheter 
can be inserted into the hemostatic seal and entirely fed through the hollow braided shaft 
of the sheath (Figure 1.13). The bi-directional deflection mechanism located on the handle 
allows the EP to deflect the distal tip of the sheath bi-directionally up to 180°. 
 
Figure 1.13. Photographs of a force-sensing ablation catheter in 
conjunction with the Agilis™ steerable sheath A, and their corresponding 
tips B. The operator now can insert, withdraw, rotate, and deflect both 
the catheter and sheath independently from one another. 
The steerable sheath provides additional degrees-of-freedom associated with catheter 
manipulation. The EP now can insert, withdraw, rotate, and deflect both the catheter and 
sheath independently from one another, which allows the EP to reach extended targets and 
manage complex anatomy. In practice, however, catheter manipulation primarily involves 
manipulating the steerable sheath (insertion, withdrawal, rotation, and deflection) and only 
inserting or withdrawing the catheter to change the amount of CF the catheter tip applies 
to the cardiac tissue (Figure 1.14). This approach is popular among recently trained 
electrophysiologists and residents entering the field. 
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Figure 1.14. Photographs of the steerable sheath handle A, and the 
catheter and sheath tips B. Manipulation primarily involves in 
manipulating the steerable sheath includes rotation (blue), insertion and 
withdrawal (green) and deflection (red). By inserting and withdrawing 
the catheter through the sheath (purple), the operator can adjust the 
amount of applied force the electrode tip exerts on the tissue. 
The MOBICATH® Sheath (Biosense Webster, Irvine, CA) and Vizigo™ Bi-Directional 
Guiding Sheath (Biosense Webster, Irvine, CA) are steerable sheaths developed by 
Biosense Webster, which have the similar operation as the Agilis™. Vizigo™ incorporates 
electromagnetic sensors incorporated at the distal tip, which allows the sheath tip to be 
visualized by CARTO® and display its position and orientation within the EAM systems. 
The Vizigo™ is the first commercially available steerable sheath that provides this 
capability. 
1.3.4 Remote Catheter Navigation Systems 
Ablation strategies to treat cardiac arrhythmia are complex, technically challenging, and 
require a high degree of skill and physical effort. To address these challenges, remote 
catheter navigation systems, utilizing both robotic and magnetic actuation technologies, 
have been developed and introduced clinically. Robotic and magnetic navigation systems 
(RNS and MNS, respectively) are appealing because they provide remote precise catheter 
navigation and have ancillary benefits, such as reducing fluoroscopic x-ray radiation 
exposure and the risk to the physician of developing orthopedic problems related to 
prolonged use of protective lead aprons. This section will describe four remote catheter 
navigation technologies developed for clinical use. 
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1.3.4.1 Amigo™ Remote Catheter System 
The Amigo™ Remote Catheter System (Catheter Precision, Mount Olive, NJ) [111] 
comprises of a robotic arm attached to the rails of a standard electrophysiology table and 
is positioned above the patient’s legs when in use. A conventional RF ablation catheter is 
inserted into the patient before being loaded into the Amigo™. The RNS is operated by a 
wired hand-held remote-control device that looks similar to the proximal handle of a 
conventional catheter. The remote control, which may be used up to 30 m away from the 
patient, provides full-range manipulation: inserting; withdrawing; rotating and deflecting 
the tip of the catheter. The Amigo™ does not incorporate separate workstations, monitors, 
or other hardware and introducing it into the catheter lab does not require additional room 
construction. The open platform approach of the system is designed to accommodate a 
range of commercially available catheters; however, the robotic system is only compatible 
with a few catheters manufactured by either Biosense Webster or Boston Scientific. 
The Amigo™ underwent its first clinical trial to evaluate its performance and safety in 
mapping the right side of the heart [112]. In the following years, several clinical studies 
have demonstrated that the Amigo™ can perform safe and effective right atrial ablation, as 
well as left atrial mapping and pulmonary vein isolation comparable to the standard 
approach [113-116]. The Amigo™ has a short learning curve and significantly reduces 
fluoroscopic x-ray radiation exposure to the operator. A drawback of the system is the lack 
of a steerable sheath limiting the manoeuvrability and stability of the catheter tip. 
1.3.4.2 Sensei® X Robotic System 
The Sensei® X Robotic System (Hansen Medical, Mountain View, CA) [117] provides 
robotic steering of two concentric sheaths (14 Fr outer and 10.5 Fr inner), through which 
any conventional ablation catheter can be inserted. The assembly is manipulated within the 
heart by a robotic arm positioned over the patient’s legs and fixed to the rails of a standard 
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electrophysiology table. The Sensei® is controlled within a separate console workstation 
positioned in the control room, which provides a 3D joystick and visual feedback to the 
EP. Manipulating the ball-like joystick changes the applied tension to the pull-wires 
embedded within the inner and outer steerable sheaths, resulting in a broad range of motion 
in any direction. If the EP uses the Artisan® X Control Catheter (Hansen Medical, 
Mountain View, CA), the incorporated force sensor within the catheter shaft detects real-
time perpendicular contact-force between the catheter tip and moving tissue. This 
information is provided visually to the physician as well as through their IntelliSense® Fine 
Force (Hansen Medical, Mountain View, CA) haptic technology. 
Although the Sensei® can be used with virtually all commercially available EAM systems, 
their CoHesion™ 3D Visualization Module (Hansen Medical, Mountain View, CA) 
specialized software was developed for robotic integration, 3D visualization, mapping and 
tracking with the EnSite™ Prevision Cardiac Mapping system (Abbott Laboratories, 
Minneapolis, MN). 
In early clinical use, the initial concern regarding the Sensei® system was the increased risk 
of perforation [118, 119]. However, more recent reports have demonstrated the feasibility 
of performing PVI without major complications [120, 121]. Unfortunately, the huge trans-
septal outer sheath limits access to critical cardiac structures such as the left ventricle and 
coronary sinus [122], which significantly limit the application of the Sensei® system to 
atrial ablation. 
In 2016, Hansen Medical was acquired by Auris Health, a medical device company that 
develops a bronchoscopic robotic navigation system. Since the acquisition, Auris has 
terminated the Sensei® platform and incorporated the technology into its platform. 
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1.3.4.3 NIOBE™ Magnetic Navigation System 
The NIOBE™ Magnetic Navigation System (Stereotaxis, St. Louis, MO) [123] is the most 
widely used remote navigation system with more than 100 active hospital installations, 300 
physicians and 9,000 procedures performed annually. NIOBE™ consists of two 
neodymium-iron-boron permanent magnets positioned on both sides of a standard 
electrophysiology table, creating a uniform magnetic field (0.08 Tesla [T]) across the 
patient’s chest [124-126]. A specialized ablation catheter, which incorporates three small 
magnets affixed to the distal tip, is navigated to target locations by first manipulating the 
magnetic field orientation. This is done by computer-aided mechanical movements of the 
external permanent magnets. The distal portion of the magnetic catheter becomes aligned 
with the new orientation of the magnetic field. The Cardiodrive® (Stereotaxis, St. Louis, 
MO) electromechanical unit is used to position the catheter along the magnetic field. Once 
the catheter is inserted into the patient’s cardiac chamber and loaded into the Cardiodrive® 
unit, all further manipulation can be done remotely from a control room utilizing a joystick, 
keyboard, or mouse control. NIOBE™ also has functional automation software designed to 
allow for automatic movement of the catheter to specific points, along with defined paths, 
in a preprogrammed motion [123]. 
The weak magnetic field in conjunction with a soft and flexible catheter provides unique 
capabilities and benefits, as demonstrated in clinical use: (1) increased precision with 
catheter movement and control; (2) reduce the risk of intermittent contact; and (3) 
decreased risk of cardiac perforation due to the compliant nature of the catheter [127]. 
However, whether these benefits translate to improved clinical success remains to be 
determined, as clinical trials of patients undergoing PVI guided by NIOBE™ versus the 
manual approach has reported mixed results [118, 125, 126, 128, 129]. 
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The NIOBE™ system also has several shortcomings, which include: (1) incredible costs 
associated with the system and room construction; (2) installation of the system in existing 
catheter laboratory requires special room shielding and additional regulation because of the 
additional permanent magnetic field; (3) since the magnetic fields are changed by 
mechanical movements, a large delay occurs between designation of magnetic field vector 
and catheter movement within the heart; (4) risk of interference with patients implanted 
with a cardiac defibrillation device; (5) the only EAM compatible with NIOBE™ is 
CARTO®; (6) the magnetic catheter cannot detect catheter-tissue CF; and importantly (7) 
due to the weak magnetic field strength the NIOBE™ system has been scrutinize by its 
users that it cannot reach adequate levels of catheter-tissue CF [122, 130, 131]. Described 
in detail in previous sections, insufficient CF results in ineffective lesion production 
correlates with reconnection gaps. 
1.3.4.4 Catheter Guidance Control and Imaging 
The Catheter Guidance Control and Imaging (CGCI, Magnetecs, Inglewood, CA) [132] is 
a non-commercial MNS that uses eight electromagnets affixed semi-spherically around the 
patient’s chest generating a dynamic 15 cm3 magnetic field within the heart [122]. The 
CGCI can navigate a specialized magnetic catheter by manipulating the field strength, 
orientation and gradient in near real-time. Similar to NIOBE™, the CGCI uses an 
electromechanical unit to advance and retract the catheter along the magnetic field vector. 
The CGCI has a maximum field strength of (0.16 T) resulting in a stronger field gradient 
(0.7 T/m). The stronger field gradient results in a maximum perpendicular force of 25 g; 
however, this has yet to be validated. The EP manipulates the catheter from a workstation 
manually, using a joystick to guide the catheter, or automatically, whereby the physician 
selects a target on display and the CGCI system plans the path and automatically moves 
the catheter accordingly. 
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The initial data collected from animal studies using the CGCI are promising [133]; 
however, clinical data are lacking. A 2010 clinical trial involving five patients was 
performed and published [134] and a second and third round of patients involving another 
74 patients performed in 2011 [132]. In 2014, a third CGCI installation commenced a 
multi-site randomized study of paroxysmal AF ablation procedures with 100 patients. The 
results from this clinical trial will provide further validation and outline a path to FDA 
clearance [132]. 
1.4 Robotic Catheter Systems in Academia 
Several robotic systems for remotely manipulating catheters during cardiovascular 
intervention have been developed in academia. These include systems for remotely 
positioning catheters guidance by different medical imaging modalities as well as 
improving lesion production. A brief overview of these projects is discussed in this section. 
The robotic catheter system proposed in this thesis is inspired mainly by the design 
approach of earlier work in our group. Thakur et al. developed a 2 degrees-of-freedom (2-
DOF) RNS designed for remote navigation during fluoroscopically guided catheterization 
[135-137]. The design of the system attempted to take advantage of the EP’s already 
acquired dexterous skill of the catheter. The preliminary work defined velocities and 
accelerations of a catheter, manipulated by an EP, during catheter intervention [138]. The 
system was then further improved by Tavallaei et al. whereby the group developed a 3-
DOF RNS designed to be compatible with MRI guidance [139-141]. The group developed 
and evaluated a novel RNS capable of remotely manipulating a catheter within the bore of 
an MRI scanner using non-ferromagnetic ultrasonic motors. 
Cercenelli et al. [142] designed and developed a versatile RNS for remote navigation of a 
standard ablation catheter. Entitled CathROB, the RNS is impressively compact has built-
in features including automatic catheter repositioning and a force-sensing mechanism 
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designed for haptic applications. The system has been evaluated in vitro and in vivo using 
an animal model. 
Several other groups have developed robotic devices to address problems relating to 
various intracardiac interventions. Notably, Dr. R. Howe’s group has developed a catheter 
RNS to assist with intracardiac mitral valve annuloplasty [143, 144]. This project included 
concepts of remote catheter manipulation and force control of a surgical instrument within 
a beating heart. The group also developed an open-source 3D-printed force sensor with an 
integrated RF electrode tip [145]. This custom force sensor, fixed to a catheter tip, was 
used to develop and evaluate a robotic system enabled with CF control of the electrode tip 
with moving tissue [146]. 
Khoshnam et al. undertook attempts to improve catheter-tissue CF using robotic platforms. 
The group developed a method to estimate CF of a catheter without an incorporated force 
sensor. The catheter tip was modelled as a large deflection beam to derive a load-
displacement relationship of the curvature of the catheter tip caused by an applied external 
force [147, 148]. Based on this preliminary work, a robotic system was developed to enable 
CF control and tested on a lab-bench setup [149]. 
The projects discussed in this section have highlighted important aspects relating to remote 
catheter manipulation and CF control. The knowledge obtained from these projects 
contributed to the overall design, architecture, and engineering approach used to develop 
and test the robotic platforms proposed in this thesis. 
1.5 Design Approach of Proposed Robotic System 
In this thesis, a novel RNS is proposed, designed to enable remote catheter navigation and 
CF control between the catheter tip and moving tissue. An operator uses an interface to 
robotically navigate a remote catheter tip to a target location within a moving cardiac 
chamber. Before the RF application, the operator can employ force control mechanism that 
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would advance the catheter and automatically adjust its position in order to maintain 
catheter-tissue CF at the desired force set by the operator. 
The proposed RNS will enable remote manipulation of conventional commercially 
available force-sensing ablation catheters permitting access to all cardiac chambers and 
preserving compatibility of existing EAM systems. The RNS will provide improved 
catheter tip stability and manoeuvrability in real-time, while at the same time reducing the 
learning curve by providing an intuitive method of controlling the robotic system. Lastly, 
but importantly, the proposed RNS will allow the EP to deliver reliably transmural RF 
ablation lesions by providing the capability to control CF between the catheter electrode 
tip and moving tissue. 
The design of the proposed RNS was inspired by the observation of modern RF catheter 
intervention in the EP lab and independent interviews with electrophysiologists and clinical 
staff. A series of formative studies were performed to acquire basic comprehension of 
manual catheter manipulation techniques. Several EPs, with a variety of clinical 
experience, participated in an in vitro phantom-based formative study. Based on these data, 
it was observed that most EPs navigate a catheter tip to targets within the cardiac chamber 
primarily using a steerable sheath. Once preliminary contact is made, the EP then inserts 
or withdraws the catheter through the sheath until an acceptable CF is experienced on the 
electrode tip. Conventional catheter manipulation technique is illustrated in Figure 1.14. 
After observing that the CF is adequate and safe, an RF application would be initiated, and 
an ablation lesion would be delivered into the tissue. This process would be repeated 
contiguously encircling the PVs and other necessary cardiac structures. 
The proposed RNS will reproduce the same manipulation technique described above, by 
providing remote control of a force-sensing ablation catheter in conjunction with a 
steerable sheath. The Steerable Sheath and Catheter Robotic Navigation System (SSC-
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RNS) will allow for full-range manipulation of a conventional steerable sheath (insertion, 
withdrawal, rotation, and deflection) in 3-DOF and permit coaxial displacement of the 
catheter (insertion and withdrawal) within the sheath in 1-DOF. This design allows for CF 
control by autonomously displacing the catheter within the sheath to ensure that the CF of 
the catheter tip is always maintained at the set level. An overview of the proposed 
architecture is illustrated in Figure 1.15. Various microcontroller-based electronics within 
the SSC-RNS receive data wirelessly from an input device and process numerous control 
algorithms, based on linear control theory, to generate proportional control signals. The 
robotic systems’ numerous motors actuate the steerable sheath and catheter (mounted 
within the SSC-RNS), replicating the motion of the input device. Furthermore, the SSC-
RNS continuously receives wireless real-time CF measurements provided by an EAM 
system (connected to a corresponding force-sensing ablation catheter) and processes a 
predictive control algorithm and generate a control signal that positions the catheter within 
the sheath under closed-loop CF control. 
The robotic system of the SSC-RNS uses an electromechanical mechanism for catheter-
tissue CF control. This device was initially designed, developed and evaluated 
independently from the SSC-RNS. The compact device aptly named the Catheter Contact-
Force Controller (CFC) was then incorporated into the SSC-RNS platform, further 
enabling remote navigation of the steerable sheath. 
The SSC-RNS is controlled remotely by an intuitive input device that is designed to utilize 
the dextrous skills and hand-eye coordination of a trained EP. The input device is fitted 
with encoders and electronics to capture the motion (insertion, withdrawal, rotation, and 
deflection) of a repurposed steerable sheath handle and wirelessly transmit the data to the 
robotic system. Manipulation of the input device results in direct robotic manipulation of 
a remote steerable sheath and catheter in real-time. The input device also provides a user 
interface enabling the operator to select navigation and force control parameters. 
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Figure 1.15. A block diagram describing the architecture of the proposed 
SSC-RNS. An EAM system tracks the location of the tip of a force-
sensing ablation catheter within a patient’s cardiac chamber and 
monitors its CF between the catheter tip and moving cardiac tissue. The 
EP then manipulates an input device, which captures the desired motion 
to be replicated a robotic system. The robotic system wirelessly receives 
position data from the input device and real-time CF measurements from 
the EAM (indicated in blue). The robotic system actuates a remote 
steerable sheath and force-sensing catheter (within the patient) according 
to the changes in the position of the input device. Furthermore, the 
robotic system can enable CF control between the catheter tip and 
moving cardiac tissue employed by the input device. 
In a clinical setting, the distal tip of the catheter and sheath would be first manually 
introduced into the patient’s cardiac chamber. The proximal handles of both the catheter 
and sheath would then be mounted into the SSC-RNS. The operator would then sit 
comfortably at the workstation of the EAM system with the input device, thereby 
decreasing fluoroscopic exposure and operator fatigue. Guided by the EAM system, the 
operator would use the SSC-RNS to navigate the catheter tip to the desired location and 
engage the catheter tip and the moving tissue. The force controller set to the desired level 
(typically between 10 g and 20 g), would be employed resulting in a CF profile with low 
variability. An RF application would then be delivered before continuing to the adjacent 
target. Point-by-point ablation would continue until the therapy is completed. 
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1.6 Thesis Overview 
This introductory chapter provided a description of AF and modern catheter-based 
therapeutic techniques, along with a brief overview of state-of-the-art commercial tools 
and technology relating to RF catheter ablation. Because this thesis is presented in an 
“integrated article format” the remaining body chapters represent publications that are 
either published, accepted for publication, or in preparation for submission, and inevitably 
some duplication of the introductory material is present. Efforts have been made to link the 
independent papers as much as possible. 
This introductory chapter provided a description of AF and modern catheter-based 
therapeutic techniques. A brief overview of the current state-of-the-art commercial tools 
and technology relating to RF catheter ablation was also described. This chapter also 
discussed the benefits and limitations of commercial remote navigation systems as well as 
novel technologies developed in academia. The outline of this thesis and the corresponding 
contributions in each chapter are as follows. 
Chapter 2 describes the design, development, and lab-bench evaluation of a novel device, 
designed by me, enabling catheter-tissue CF control. A custom-built linear motion stage, 
capable of reproducing clinically relevant motion, was used to evaluate the force control 
performance of the CFC. CF profiles of a catheter engaging with tissue-mimicking material 
were recorded with and without the use of the CFC (representative of manual intervention). 
Manual and CFC-assisted CF profiles were compared with one another. A version of this 
chapter, entitled “Design and Evaluation of a Catheter Contact-Force Controller for 
Cardiac Ablation Therapy,” has been published in IEEE Transactions on Biomedical 
Engineering (vol. 63, no. 11, pp. 2301-2307, 2016). 
Chapter 3 further evaluates the CFC in vitro to examines its impact on RF lesion 
production. CFC-assisted RF ablation lesions were delivered to moving tissue at different 
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clinically relevant force levels and were compared to lesions delivered in tissue in the 
absence of motion. CFC-assisted ablation lesions were also compared to lesions without 
force control representing manual catheter intervention. Furthermore, the CFC was also 
tested in vivo in a pig model to evaluate its force control performance in a beating heart. A 
version of this chapter, entitled “Eliminating the effects of motion during radiofrequency 
lesion delivery using a novel contact-force controller,” has been accepted for publication 
to the Journal of Cardiovascular Electrophysiology. 
The work in Chapter 4 incorporates the CFC technology into a robotic platform that enables 
remote navigation of the steerable sheath and force-sensing ablation catheter. In a lab-
bench study, an operator robotically navigated a remote catheter tip to stationary and 
moving targets within a contractile motion phantom. The operator employed the force 
controller on moving targets to a set amount of force. Catheter tip-target accuracy and 
force-controlled profiles were compared to a repeat experiment where the tasks were 
performed manually. A version of this chapter, entitled “Remote catheter navigation and 
contact-force control: design and evaluation of a novel steerable sheath and catheter 
robotic navigation system,” is in preparation for submission to IEEE Transaction on 
Biomedical Engineering. 
Chapter 5 provides a summary of the accomplishments and contributions of the thesis, 
followed by suggestions for future work that uses the CFC to improve understanding of the 
effects of contact force on lesion production and translation of the device into clinical use. 
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2 Design and Evaluation of a Catheter Contact-
Force Controller 
This chapter is adapted from “Design and Evaluation of a Catheter Contact-Force 
Controller for Cardiac Ablation Therapy.”1 
My contribution to this chapter involved (i) designing and developing the catheter contact-
force controller, (ii) designing and developing phantoms, (iii) conducting experiments, (iv) 
collecting and analyzing data, and (v) writing manuscripts. 
 
2.1 Introduction 
Percutaneous radiofrequency (RF) catheter ablation is becoming the standard of care for a 
variety of cardiac arrhythmias. Cardiac electrophysiologists (EP) introduce ablation 
catheters into the heart and manipulate them until the distal tip contacts the targeted 
myocardium. Once reached, RF power is delivered to form ablation lesions that interrupt 
the electrical pathways responsible for the arrhythmia. For successful treatment, it is vital 
                                                           
1
Gelman D, Tavallaei MA, Skanes AC, Drangova M. “Design and Evaluation of a Catheter Contact-Force 
Controller,” IEEE Transactions on Biomedical Engineering (vol. 63, no. 11, pp. 2301-2307). Permission 
for reproduction provided in Appendix A. 
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that these lesions are transmural, as superficial lesions leave areas of healthy cardiac tissue 
that may result in conduction recurrence and ablation failure. 
Catheter tip-to-tissue contact force (CF) is an indicator for assessing lesion development 
[1-5], and CF guidelines have been established to label a delivered lesion as effective [6-
8]. Additional studies have shown that monitoring both the duration of the delivery and CF 
at a specific RF power can predict lesion volume [3, 6-11]. Conventionally described as 
the Force-Time Integral (FTI), the model may be used as a prospective quantitative tool to 
determine lesion volume under defined parameters. Unfortunately, this model is dependent 
on catheter stability, and while used in the clinic as a guide, it has not been used as a 
quantitative metric that can predict lesion volume or transmurality. Finally, lesions 
delivered with excessive CF present a risk of deep tissue overheating, which may result in 
“steam pop,” perforation and injury outside the heart, including esophageal, pulmonary and 
phrenic nerve damage [2]. These potential risks often inhibit the EP and cause them to 
deliver the lesion tentatively, with a lower level of CF to lessen the risk of injury. Clinically, 
CF information is often used as a guide to ensure catheter tip contact and confine the CF 
within acceptable ranges, but is ultimately limited by tissue motion, as seen in the CF 
profile in the lower right-hand corner of Figure 2.1. 
While ideally, the CF should be regulated within a prescribed range, EP cannot respond 
fast enough to compensate for cardiorespiratory motion [12]. Approaches to minimize 
cardiac motion during ablation, have been proposed, including high-frequency-jet 
ventilation [13]. None have successfully provided a motionless environment in all patients 
[14]. Kesner et al. [15] demonstrated CF control of catheters and instruments used for 
mitral valve repair; however, the implementation does not address problems associated 
with catheter ablation. 
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Figure 2.1. Modern electromagnetic catheter tracking systems 
(CARTO® 3, Biosense Webster, Irvine, CA) enable visual feedback of 
the real-time CF experienced on the tip of the catheter 
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, 
CA). The figure is a snapshot demonstrating catheter location in the 
rendered LA (white with green tip) and the CF as a function of time in 
the lower right-hand corner. Note the variation in CF with 
cardiorespiratory motion. Image courtesy of London Health Science 
Center. 
Commercial force-sensing ablation catheters enable the EP to simultaneously monitor the 
CF in real-time while delivering the lesion, as illustrated in Figure 2.1. Often these 
catheters are used together with steerable sheaths, whose added level of versatility and 
stability has increased clinical success [13, 16, 17]. The EP typically manipulates the 
steerable sheath until the catheter is pointing at the target region, and then advances the 
catheter forward through the sheath until the desired level of CF is imparted onto the tissue. 
In this chapter, we introduce a tool that enables the delivery of effective RF lesions by 
autonomously regulating the CF of a force-sensing ablation catheter, based only on the 
real-time CF measurements. The Catheter Contact-Force Controller (CFC) is a hand-held, 
modular device that enables robotic control of the catheter within the sheath, which 
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otherwise would be done manually by the interventionalist. The CFC is an add-on tool 
compatible with commercially available, pre-existing force-sensing ablation catheters and 
sheaths. 
2.2 System Description 
Incorporation of the CFC replaces the manual manipulation of the catheter through the 
sheath. Rather than advancing the catheter forward until a sufficient CF level is reached, 
the interventionalist would engage the CFC, which monitors the CF in real-time and 
updates the position of the catheter to maintain the CF experienced at the tip of the catheter 
at the desired level, despite the motion of the target tissue. The CFC system comprises a 
hand-held, compact, electromechanical device and an embedded system.  
2.2.1 Hand-Held Device 
The hand-held CFC device, Figure 2.2, is mechanically clamped to the distal end of the 
sheath handle (i.e., at the hemostatic seal and insertion point of the catheter). A catheter-
locking adapter rigidly clamps the catheter shaft onto a precision linear actuator (LM 2070, 
MICROMO, Clearwater, FL) travelling along a 12 mm diameter 134 mm long precision 
magnetic shaft. Movement of the actuator directly translates to movement of the catheter 
through the sheath. The specific linear actuator selected in the design was selected based 
on velocity, acceleration and torque requirements described in Appendix B. 
The adapter and actuator are mounted within an enclosure, which is designed to securely 
lock onto the sheath handle while keeping the catheter concentrically mounted within the 
hemostatic seal. A set of hinges and latches enables easy clamping and removal of the CFC. 
Both the adapter and enclosure were fabricated in polypropylene using additive 
manufacturing (Objet3D Pro, Stratasys, Eden Prairie, MN). 
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Figure 2.2. Schematic side-view, A, and photograph top-view, B, of the 
electromechanical hand-held CFC attached to a steerable sheath and 
force-sensing ablation catheter. Movement of the linear actuator along 
the fixed magnetic rod moves the catheter through the hemostatic seal of 
the sheath handle. 
2.2.2 Hybrid Control System 
To maintain a prescribed CF between the tip of the catheter and a moving target, we 
implemented a hybrid control system. Traditional closed-loop proportional-integral-
derivative (PID) control algorithms are based on minimizing the error between the desired 
and actual inputs and are a viable solution in robotic catheter control systems [18-21]. The 
CFC uses a hybrid PID controller, a slight variation of a standard PID controller, whose 
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where the error e(t) is the difference between the desired and current contact forces, FD and 
FC(t) respectively. The control parameters KP, KI and KD generate a different control signal 
depending on the error measured in real-time. If the error is larger than a predefined CF 
threshold, FT, the control system is in an “aggressive” state indicated by KPA, KIA, KDA. 
When the error is lower than FT, the control system operates in a “conservative” state 
indicated by KPC, KIC, KDC. The CF threshold was empirically assigned to be 5 g – a level 
that was observed to retain steady-state accuracy. 
Tuning of the aggressive control parameters was achieved using the Tyrues-Luyben tuning 
method, as implemented by [22]. The conservative control parameters were manually tuned 
for a desired steady-state response; in the current implementation, the conservative control 
parameters were at least a factor of 4 smaller than the aggressive ones. 
2.2.3 Electronic Hardware Design 
The hybrid control system was implemented within an embedded electronic system, 
enabling real-time control of the linear actuator. A microcontroller development platform 
based on a Atmel SAM3X8E 84 MHz 32-bit ARM architecture (Arduino Due, Arduino, 
Turin, Italy) generates a pulse-width modulated (PWM) control signal, based on the 
measured and desired CF, which acts as input to the linear actuator controller and driver 
circuitry (MCLM 3003, MICROMO, Clearwater, FL). This daughter-board is programmed 
with a native velocity proportional-integral (PI) controller that controls the speed of the 
motor based on the input PWM signal. Tuning of the PI controller was performed using 
the manufacturer’s tuning software, before tuning the hybrid PID system. The update rate 
of the hybrid PID system was set to 1 kHz, which was the maximum rate of the linear 
actuator controller. A sampling rate exceeding 300 Hz will meet all requirements. This 
figure is based on “best practice,” which is to sample the force data at a rate ten times faster 
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than the time constant associated with the open-loop response of the system. Figure 2.3 is 
a block diagram of the designed embedded system. 
 
Figure 2.3. Block diagram of the CFC control system. 
2.2.4 Linear Motion Phantom 
To evaluate the CFC’s ability to regulate CF on a moving target in vitro, a custom-built 
linear motion phantom was developed (Figure 2.4). The motion phantom was built to 
provide sinusoidal and physiologic motion profiles. A gear motor with a Hall effect 
encoder (37D Gearmotor, Pololu, Las Vegas, NV) drives a lead screw mechanism 
providing linear motion to a carriage. A second PID control system within an embedded 
electronic system controls the motion stage: the circuit board assembly includes a 
microcontroller development platform (Arduino Due, Arduino, Turin, Italy) and a DC 
motor driver daughter-board (VNH5019 Motor Driver Carrier, Pololu, Las Vegas, NV). A 
strain gauge capable of detecting the force with 200-milligram resolution (S100, Strain 
Measurement Devices, Wallingford, CT), coupled to a linear amplifier (CSG110, FUTEK, 
Irvine, CA), is mounted on the carriage and used to measure the CF of the tip of the 
catheter. The force signal provided by the strain gauge is a surrogate to the real-time force 
signal provided by the catheter tip. A silicone membrane (Dragon Skin 30, Smooth-On, 
Macungie, PA) is positioned between the strain gauge and the tip of the catheter to mimic 
soft tissue compliance. A setscrew fixes the sheath firmly in place without hindering the 
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movement of the catheter housed within the sheath. Linear calibration, according to 
Hooke’s law, was first performed to determine the relationship between the displacement 
of the tissue and the force measured by the strain gauge. 
 
Figure 2.4. Linear motion phantom with the catheter and sheath loaded, 
used to evaluate the CFC. The linear motion imposed on the tip of the 
catheter simulates myocardial tissue motion. 
The phantom was programmed to execute arbitrary sinusoidal and sine-sweep motion 
profiles and to replicate physiological motion. CF profiles were recorded by force-sensing 
ablation catheters during typical ablation procedures, similar to the profile illustrated in 
Figure 2.1. These profiles, containing both high-frequency low-amplitude cardiac and 
low-frequency high-amplitude respiratory motion, were programmed into the motion 
phantom as position trajectories, using the linear calibration parameters. 
The signal from the strain gauge, measured in real-time, was used as the CF feedback signal 
of the CFC control system (Figure 2.3) and represented the CF signal that would be 
provided by a commercial force-sensing ablation catheter. Real-time CF data from 
proprietary catheters is not available routinely and could not be integrated with the CFC at 
the time of these experiments. 
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2.3 System Evaluation 
2.3.1 Linear Motion Phantom Evaluation 
The linear motion phantom was first evaluated to ensure that the executed motion profiles 
mimic the physiological motion that results in CF profiles similar to those measured 
clinically. The catheter was held fixed while the linear motion phantom imposed 16 
different patient-specific motion profiles. The sheath was locked in place for half of the 
experiments. The real-time CF measurements provided by the strain gauge were recorded 
and compared to the corresponding CF profiles. No attempt was made to perfectly match 
the executed CF profiles to the corresponding patient profiles, and the measured CF 
profiles were only inspected visually, ensuring the range of amplitudes and frequencies 
were within the physiologic range. 
2.3.2 Catheter Contact-Force Controller Evaluation 
Experiments were performed to evaluate the overall accuracy and dynamic performance of 
the CFC. For these experiments, the CFC was attached to the rear end of a commonly used 
steerable sheath (Agilis™ NxT, St. Jude Medical, St. Paul, MN) and force-sensing ablation 
catheter (THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) 
combination. Water was introduced via the sheath’s side port to mimic the clinical setting 
and reduce the friction between the sheath and catheter. The distal portions of the sheath 
and catheter were inserted into the linear motion phantom, as illustrated in Figure 2.5.  
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Figure 2.5. The experimental setup used to evaluate the performance of 
the CFC. A is a line drawing (not to scale) showing the CFC, B sheath 
and catheter mounted with the linear motion phantom; photographs of 
the CFC C, and motion phantom D are also shown. 
2.3.2.1 Step Response 
The response of the CFC control system to a step input (of 25 g) was first evaluated. The 
step response was then measured during 25 repeats and the rise time, overshoot, and peak 
level were characterized. During these experiments, the linear motion phantom was kept 
fixed. 
2.3.2.2 Safety 
It is vital to ensure that the CFC can respond to excessive, fast and sudden motions that 
may result in tissue perforation. The linear motion phantom was programmed to impose a 
bi-directional continuous sine sweep motion profile, sweeping from 0.1 Hz to 2.5 Hz with 
an amplitude of 70 g peak-to-peak. This unlikely clinical scenario was selected following 
Fourier analysis of over 40 patient-specific CF profiles and determining that the maximum 
frequency component observed was 2.5 Hz. While the phantom executed the prescribed 
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motion, the CFC was engaged and attempted to regulate the CF to the desired reference of 
25 g. The maximum error between the desired and actual CF was measured. This 
experiment was repeated 10 times. 
2.3.2.3 Patient-Specific Dynamic Response 
To evaluate the overall performance of the CFC versus manual intervention, the linear 
motion phantom was programmed to execute 16 different patient motion profiles. Prior to 
any evaluation of the CFC, a control experiment was performed whereby the phantom 
replicated each profile with the CFC’s disabled. This is representative of manual 
intervention, where the EP contacts the catheter to moving cardiac tissue and holds the 
catheter still to deliver a lesion. The experiment was then repeated with the CFC 
programmed to deliver 15 g, 25 g, and 40 g for the duration of the motion profile. Statistical 
analysis of the regulated CF profiles was performed to calculate mean, confidence interval, 
and root-mean-square error (RMSE). Histograms of CF were also plotted for the “manual” 
and CFC interventions. Note that for this study, we use the term “manual” to refer to the 
CF profile representative of CF profiles recorded during clinical ablation procedures. 
2.3.2.4 Force-Time Integral 
This experiment was designed to demonstrate that the CFC could be used not only to 
regulate the delivered force but also to deliver lesions with prescribed FTI. The CFC was 
programmed to deliver a prescribed FTI at the desired CF while the linear motion phantom 
imposed a patient motion profile. For each combination of set CF and FTI levels, an 
expected duration can be calculated. The CFC was programmed to monitor the FTI, and 
automatically retract the tip of the catheter back into the sheath once the desired FTI was 
reached. The generated CF profile and duration of catheter engagement was recorded and 
compared with expected values. This experiment was then repeated for various 
configurations of FTI and CF, which may be user-defined in a clinical setting. The tested 
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FTI values were 500, 1000, and 1500 gs, where each was repeated with 25 g and 40 g of 
CF. Each configuration was repeated 3 times. 
2.4 Results 
2.4.1 Linear Motion Phantom 
 
Figure 2.6. Two representative patient CF profiles (A and C) and the 
corresponding CF profiles (B and D, respectively) imposed on a fixed 
catheter tip by the linear motion phantom, executing the same patient 
profile. The motion profiles depicted in B and D are profile #13 and #3 
in Figure 2.8D, respectively. 
The linear motion phantom was able to replicate a range of patient-specific CF profiles. 
The profiles chosen to evaluate the CFC are characteristic of typical cardiorespiratory 
patterns depicted in Figure 2.6A as well as irregular profiles associated with patient motion 
or catheter instability depicted in Figure 2.6C. The generated CF curves, shown in Figure 
2.6B and Figure 2.6D, visually demonstrate a high level of similarity to the corresponding 
clinically acquired profiles (Figure 2.6A and Figure 2.6C). These results demonstrate that 
the linear motion phantom can replicate cardiorespiratory forces that are typically 
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encountered during catheter RF delivery and is appropriate to be used as a phantom for the 
CFC’s evaluation. Locking the sheath in place did not affect the results. 
2.4.2 CFC Performance 
2.4.2.1 Step Response 
The response of the CFC’s control system to a 25 g step input is shown in Figure 2.7. The 
following step response characteristics were calculated from the measurements: 38 ± 3 ms 
rise time, 3 ± 2 g overshoot, and a peak of 29 ± 2 g; means and standard deviations of 25 
repeats of the step response are reported. The negligible overshoot and oscillation indicate 
that the tuning method used to determine the control parameters has resulted in a desired 
transient and steady-state response. 
 
Figure 2.7. Step response of the CFC for a set force level of 25 g. At 
every time point, the mean and standard deviation are plotted. 
2.4.2.2 Safety 
During the control of a 70 g peak-to-peak sine sweep from 0.1 Hz to 2.5 Hz, the maximum 
difference between the prescribed and measured CF was 15 ± 2 g, with all measured CF 
values being below 42 g. These results demonstrate that the CFC is capable of reacting to 
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sudden changes in tissue displacement that would otherwise result in large spikes of CF 
and potentially cause tissue damage. 
2.4.2.3 Patient-Specific Dynamic Response 
 
Figure 2.8. Histograms A-C show the distribution of manual and CFC-
controlled CF for three unique motion profiles (16,15, and 9 from panel 
D, respectively). The manual intervention histograms indicate that: A 
majority of time was spent while CF was low (less than 20 g), B 
significant myocardial motion resulting in greatly fluctuation CF, and C 
a precise lesion was delivered but the force was not centred at the 25 g 
target. In each case, CFC-control brings the mean CF to the target. 
Histograms of manual D and CFC-controlled E interventions, 
represented as grey scale values, show a significant difference in CF 
distribution for all 16 motion profiles. 
The CFC was able to significantly improve the CF profile in comparison to manual 
intervention (p < 0.001). Figure 2.8A through Figure 2.8C depicts the distribution of 
measured CF for three motion profiles, representative of CFs measured during the delivery 
of different lesions; histograms are plotted for both manual and CFC-controlled 
interventions, with a prescribed CF level of 25 g. The images in Figure 2.8D (manual) and 
Figure 2.8E (CFC-controlled) are grey-scale representations of the CF histograms for all 
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16 motion profiles; they clearly demonstrate that when the CFC is engaged the prescribed 
mean force is achieved for all motion profiles. 
Similar performance was achieved regardless of the magnitude of the prescribed CF. 
Illustrated in Figure 2.9, are the results for one representative experiment where the CFC 
was programmed to deliver a CF of three clinically relevant levels – 15 g, 25 g, and 40 g. 
Consistently similar force distributions were achieved regardless of the prescribed CF 
value. Detailed performance metrics – averaged over all tested motion profiles – are shown 
in Table 2.1 for the three prescribed CF levels. 
 
Figure 2.9. A original CF profile (green), while the CFC was disabled. 
B illustrates the generated CF profile while the CFC was engaged to 
deliver 15 g (cyan), 25 g (orange) and 40 g (navy). Histogram C and 
grey-scale representation D illustrate the CF distribution between 
manual and CFC intervention at various desired CF levels. The motion 
profile depicted here is profile #1 from Figure 2.8D. 
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Prescribed CF (g) 15 25 40 
5% Percentile 10.1 ± 1.2 19.7 ± 1.2 34.3 ± 1.2 
95% Percentile 20.6 ± 1.3 31.1 ± 1.5 46.9 ± 1.7 
Mean 15.3 ± 0.1 25.4 ± 0.1 40.4 ± 0.1 
RMSE 3.2 ± 0.6 3.4 ± 0.7 3.9 ± 0.8 
Table 2.1. All measurements are presented in grams (g) of force. Mean 
and standard deviation of all 16 profiles are reported. 
2.4.2.4 Force-Time Integral 
For all experiments performed to demonstrate that the CFC could achieve a target FTI, the 
CFC successfully engaged the catheter with the desired CF until a target FTI was reached. 
The results obtained with each configuration of FTI and CF are presented in Table 2.2. 














25 20 500 25.7 ± 3.0 19.49 ± 0.01 
40 12.5 500 40.7 ± 3.5 12.29 ± 0.01 
1000 
25 40 1000 25.4 ± 3.1 39.36 ± 0.04 
40 25 999 40.4 ± 3.4 24.71 ± 0.01 
1500 
25 60 1500 25.3 ± 3.0 59.27 ± 0.06 
40 37.5 1499 40.4 ± 3.4 36.99 ± 0.22 
Table 2.2. Results obtained with each configuration of FTI and CF 
tested. The measure CF and duration are comparable to the expected 
outcome. 
A representative experiment is illustrated in Figure 2.10. The lesion delivery time was 
within 480 ± 199 ms of the expected duration. This is indicative of a regulated CF profile 
throughout the delivery, as excessive CF would result in short lesion delivery times and 
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low CF levels would result in the opposite. With each configuration of desired CF and FTI, 
a similar profile was generated with an expected and predictable deviation. 
 
Figure 2.10. Interval 0-30 s, the catheter was in contact with the phantom 
while the CFC was disabled. Interval 30-49.5 s, the CFC was engaged to 
deliver 500 gs at 25 g. Interval 49.5-55 s, the tip of the catheter retracted 
into the sheath once the desired FTI (red) had been reached. The motion 
profile depicted here is profile #15 from Figure 2.8D. 
2.5 Discussion 
We have presented a novel and easy-to-use tool that regulates the CF imparted by standard 
ablation catheters on moving tissue regardless of the type of motion imposed. The compact 
hand-held device is used with commercially available force-sensing ablation catheters and 
steerable sheaths, which are widely used in modern EP labs. The presented CFC utilizes 
the same tools and information available to the interventionalist but grants the ability to 
regulate CF and FTI. 
While CF measurement (at the tip of an ablation catheter) has been available to the EP for 
some time, it has been used primarily as a visual guide to determine if adequate contact has 
been made or if there is a risk of tissue perforation. The CFC has been demonstrated to 
control the force at the tip of the catheter to within a few grams of a prescribed force level. 
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The CF profiles, recorded during clinical ablation procedures, used to impart clinically 
relevant motion for evaluating the CFC and shown in Figure 2.8 demonstrate some of the 
problems associated with ablation delivery. For example, profile #16 (Figure 2.8A) 
represents a lesion where negligible force existed between the catheter tip and the wall 
during most of the time RF power was being delivered; when the CFC was engaged the 
mean CF was increased to 25 g, as prescribed. Similarly, the scenario depicted in Figure 
2.8B demonstrates large variations in CF (manual) due to motion, which is corrected via 
the use of the CFC, reducing the RMSE (about 25 g) from 15.1 to 5.5 g. Even when a tight 
distribution of forces is achieved manually, as in Figure 2.8C, the mean CF may not be at 
a level sufficiently high for the delivery of a transmural lesion – use of the CFC, in this 
case, shifts the distribution of CF from being centred about 15 g to being centred about 25 
g. Consistently narrow, and symmetric, distributions of CF were also achieved for different 
prescribed CF levels (Figure 2.9, Table 2.1). 
Successful control of CF over the duration of lesion “delivery” also enabled control of FTI. 
Automatic engagement and retraction of the catheter for specified FTI at the desired CF 
has the potential to become a fundamental and powerful tool in the EP lab. While FTI has 
been proposed as a useful measure in predicting lesion transmurality and volume, without 
a device like the CFC, FTI cannot be easily used as a metric clinically or in preclinical 
studies aimed at optimizing lesion delivery parameters.  
The study evaluating the performance of the CFC under conditions of rapidly varying 
motion have also demonstrated that the use of the CFC clinically has the potential to 
minimize tissue damage due to excessive force. The CFC was able to compensate for 
changes in CF as fast as 700 g/s and maintain CF within 15 g of the prescribed values. 
These results are significant because they indicate that using the CFC, forces able to 
perforate tissue [23] would never be achieved.  
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The CFC was designed as a hand-held device that would enable the interventionalist to 
engage it at any point during a complete ablation procedure but is free to perform all other 
tasks as is done under current clinical practice. The CFC can easily be removed from the 
catheter and sheath assembly to ensure optimal catheter steerability and be re-clamped 
when a target location has been reached, just prior to RF power delivery. The device is 
versatile and can be used as a stand-alone CF control aid or can be incorporated with 
catheter robotic navigation systems for further improvements in position and force control. 
Ongoing in vitro and in vivo studies aim to demonstrate the full effectiveness of the CFC 
in controlling lesion volume. 
2.6 Limitations 
Despite the extremely promising results, it is important to note that the study is limited by 
the fact that the motion of an in vitro dynamic phantom was used as a surrogate for contact 
force measured at the catheter tip during CFC evaluation; the limitation is manifested in 
two ways. First, using a strain gauge positioned behind tissue-simulating silicone to 
provide CF measurements introduced damping of the CF that would have been measured 
at the tip of the catheter (i.e. at the interface of the catheter and silicone). Implementation 
of the CFC with a force-sensing catheter would require re-tuning of the control parameters 
to account for the different dynamics. Second, for the phantom based experiments, the 
acquired CF data were implemented as linear motion profiles with the catheter placed 
perpendicular to the surface of the tissue. This experimental design assumed that the 
catheter was oriented the same way during the acquisition of the clinical data. If clinically, 
the catheter tip was oriented at an oblique angle, larger motion profiles would correspond 
to the measured forces. All tested force profiles were collected in different parts of the left 
atrium within a single patient. This has implications as the phantom has a perpendicular 
only approach and may not simulate the catheter extended at an angle or with a curve. It is 
likely, however, that the exact characteristics of cardiac tissue motion will contain the same 
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frequency components as the profiles used in this study, which ultimately does not affect 
the implemented control system of the CFC. 
All CF profiles used to evaluate the CFC were acquired from patients undergoing 
pulmonary vein isolation ablation therapy and may not be representative of the CF profiles 
measured during ablation therapies of the left ventricle. During left ventricular ablation 
procedures CF may change more rapidly due to systolic motion. The safety experiments 
performed as part of the present study contained CF waveforms with high changes of CF, 
larger than would be expected in ventricular ablations, and these preliminary tests provide 
confidence that the CFC will be able to control force even during ventricular ablations. 
In all experiments, the distance between the tip of the catheter and the tip of the sheath was 
limited to less than 30 mm. Based on interviews with cardiac electrophysiologists, when 
using a steerable sheath, it is uncommon to exceed this distance. The performance of the 
CFC has not been tested with greater distances. Furthermore, it is important to note that 
the CFC will only work correctly when the catheter is adequately supported by the sheath 
at the distal tip. As such, significant catheter deflection and extension may compromise 
CFC performance. 
2.7 Conclusions 
This study represents the first demonstration of contact force control using a versatile hand-
held catheter contact force controller, which can be coupled to any force-sensing ablation 
catheter and steerable sheath combination. The demonstrated control of contact force under 
varying motion conditions is promising and suggests that – when implemented in 
combination with a force-sensing catheter – the CFC can deliver prescribed ablation 
lesions.  
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3 Eliminating the Effects of Motion during RF 
Ablation Delivery 
This chapter is adapted from “Eliminating the Effects of Motion during Radiofrequency 
Lesion Delivery using a Novel Contact-Force Controller.”2 
My contribution to this chapter involved (i) integrating technologies, (ii) developing novel 
control systems, (iii) designing and developing phantoms, (iv) designing and conducting 
experiments, (v) collecting and analyzing data, and (vi) writing manuscripts. 
3.1 Introduction 
Catheter-tissue contact force is a major determinant of catheter ablation lesion size 
uncertainty during radiofrequency (RF) power application [1-5]. Insufficient contact force 
results in inadequate lesion production and increased AF recurrence rates [6-8], while 
excessive contact force is associated with tissue over-heating, increased incidence of steam 
pops, perforation, thrombus formation, and collateral tissue damage to the esophagus and 
phrenic nerve [2, 9-13]. In addition to the average force, contact-force variability has been 
shown to be an essential parameter in determining RF lesion formation [14]. Improving 
                                                           
2
Gelman D, Skanes AC, Jones DL, Timofeyev M, Baron T, Drangova M. “Eliminating the Effects of 
Motion during Radiofrequency Lesion Delivery using a Novel Contact-Force Controller,” Journal of 
Cardiovascular Electrophysiology (Accepted). 
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contact-force stability enables RF power to be effectively deposited within the tissue and 
not the surrounding blood pool, and this, in turn, could be critical to achieving long-term 
success [15]. 
A recent meta-analysis, summarizing all randomized controlled trials investigating contact 
force in AF ablation, reports that contact force variability, rather than average force alone, 
has emerged as a critical element that governs lesion size and ablation outcomes [16]. The 
EFFICAS II trial demonstrated durable PVI using a contact-force target of 20 g, with a 
narrow range between 10 g and 30 g [4]. Similarly, the SMART-AF trial showed an 
increase in clinical success when more time was spent within a pre-defined force range (i.e. 
reduced force variability) [15]; operators who stayed within a selected range for more than 
80% of the time during RF applications were more than 4 times more likely to have clinical 
success in comparison to those who did not. In further studies, Ullah et al. [17] showed 
that, for the same accumulated FTI, RF ablation lesions delivered with contact-force 
variation less than 5 g significantly increased impedance drops and achieved higher 
maximums compared to lesions with greater variation [17]. The authors of this study 
suggest that improving force stability rather than merely delivering more FTI can produce 
more effective lesions. In a similar study, Makimoto et al. [18] found that a relative 
standard deviation less than 30% of the mean force (e.g. 10 ± 3 g or 20 ± 6 g) correlated 
with a reduction in reconnection gaps during PVI [18]. Both of these studies identified 
regional locations typically associated with AF reconnection, such as the LA roof, with 
parameters demonstrating high contact-force variability. 
Despite this evidence, in clinical practice, it is virtually impossible to maintain sufficient 
average contact force and reduce contact-force variability reliably [18-22]. The 
adjustments made by an operator are limited by human factors (perception and reaction 
time) and system delays (including time required to average and display a mean force 
level), making it impossible to compensate for force variability in real-time and 
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highlighting the clear need for new technology to control catheter-tissue contact force and 
optimize catheter ablation techniques. 
In our previous work [23], we developed and evaluated a catheter contact-force controller 
(CFC) that monitors catheter-tissue contact force in real-time and simultaneously adjusts 
the position of the ablation catheter within a sheath to compensate for variations in contact 
force that occur due to cardiorespiratory motion. Preliminary lab-bench tests demonstrated 
that using the CFC resulted in significant improvement in the stability and control of 
catheter-tissue contact force on moving tissue-mimicking material. 
The aim of the present study was to demonstrate the ability of the CFC to maintain a set 
level of force in vivo and determine the device’s impact on lesion production when 
compared to manual intervention. In the first part of the study, the device was tested in a 
porcine model in vivo, where an experienced electrophysiologist attempted to maintain a 
set force level with and without the assistance of the CFC. In the second part of the study, 
an in vitro contractile bench model tested the hypothesis that the CFC helps deliver 
prescribed and reproducible ablation lesions despite the presence of clinically relevant 
tissue motion under fixed conditions of RF power and duration. In these experiments, the 
sizes of lesions delivered to moving tissue samples with and without the CFC were 
compared to lesions delivered to stationary tissue. 
3.2 Methods 
3.2.1 Catheter Contact-Force Controller 
The CFC is a simple add-on to a conventional force-sensing catheter used in conjunction 
with a steerable sheath, as described in detail in Chapter 2 [23]. Briefly, the CFC actuation 
unit is clamped onto the back-end of a steerable sheath near the hemostatic seal (Figure 
3.1); a linear motor clamped onto the catheter shaft via a locking adaptor adjusts catheter 
motion with respect to the sheath. The CFC’s embedded electronics monitor the CF in real-
3.2 Methods 76 
 
time and use 1 of 2 control algorithms to adjust the catheter position within the sheath in 
order to maintain constant force at the catheter tip. 
 
Figure 3.1. Schematic diagram A and photograph B of the CFC 
actuation unit attached to an ablation catheter and steerable sheath. A 
locking adaptor clamps the CFC to a linear actuator (shown in B), which 
enables the catheter to be displaced axially within the sheath. 
First, a model-based adaptive control system [24] was implemented to assist in cases where 
gradual changes in CF are required (e.g. respiratory motion). However, such adaptive 
algorithms perform poorly in the presence of large, rapid fluctuations of CF, such as those 
caused by systolic-diastolic motion. To address this, an additional control system, which 
uses repetitive control [25], was implemented. Specifically, the repetitive control system 
uses the heart rate, derived from the ECG, as a priori information to improve disturbance-
rejection performance during the presence of fast-moving periodic cardiac motion. In the 
current implementation, the user selected the control mode (adaptive versus repetitive) 
based on the observed CF profile. Further detail about the two control systems is presented 
in Appendix C. 
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3.2.2 Force Control Performance In Vivo 
Animal studies were performed in accordance with institutional and national guidelines 
and approved by the University of Western Ontario Animal Use and Care Committee 
(Protocol #2013-064, Appendix D). Two male farm pigs weighing approximately 35 kg 
were used for the study. 
 
Figure 3.2. Photograph of the CFC, left, and the in vivo experimental 
setup, right. 
Using standard procedures, each pig was anesthetized and prepared for catheterization [26]. 
Each pig was intubated, and the ventilation rate was set for 20 BPM. A research-based 
electro-anatomical catheter mapping system (CARTO® 3, Biosense Webster, Irvine, CA), 
mobile C-arm fluoroscopic x-ray unit (OEC 9900 Elite, General Electric, Boston, MA), 
and intracardiac echocardiography system (Acuson Sequoia, Seimens, Munich, Germany) 
were used to assist catheter navigation (Figure 3.2). A steerable sheath (Agilis™ NxT, 
Abbott Laboratories, St. Paul, MN) and a force-sensing ablation catheter 
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) with the CFC 
attached were inserted into the heart via right femoral access. A pace-making lead attached 
to an external generator was introduced via the right jugular vein and placed in the superior 
RA to provide cardiac pacing at 115 BPM throughout the experiment. A shaped trans-
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septal needle (Brockenbrough, Medtronic, Minneapolis, MN) was introduced via the left 
femoral vein and used to gain access to the left side of the heart, under the guidance of an 
intracardiac echocardiography catheter (Acuson AcuNav, Seimens, Munich, Germany). 
A skilled electrophysiologist (A.C.S.) manipulated the catheter and steerable sheath to 
target locations in the LA, RA and LV. At each location, the physician attempted to 
maintain 20 g for 30 seconds with manual catheter intervention. The CFC was then enabled 
and set to maintain the force at 20 g. For all interventions, the catheter tip was maintained 
perpendicular to the surface of the tissue to mimic ideal ablation conditions and maximize 
motion-related force variability; a catheter-tissue incidence angle of between 0° and 45° 
from normal was considered perpendicular, as defined by Ullah et al. [17]. The electro-
anatomical mapping system continuously displays the force angle, and experiments were 
performed only when perpendicular catheter angle was achieved. It is important to note 
that the anatomy of the pig LA is quite different from the human. Most importantly, the 
PV region is often a confluence with minimal musculature. Also, the LA appendage is very 
large and makes up a large portion of the surface area. Sites in the LA were targeted as 
follows; after transseptal access was obtained the catheter was advanced to the LA 
appendage, withdrawn to the LA roof and turned posteriorly to the posterior LA wall to 
allow sampling of several sites within the LA. 
Contact-force profiles of manual and CFC-assisted interventions were recorded and 
compared. The average contact force and variation were calculated for manual and contact-
force-controlled experiments. Variability in contact force and was calculated as contact-
force variation (CFV) [17] – i.e. the difference between the mean trough and peak forces – 
as well as the relative standard deviation (RSD) or the coefficient of variation [18]. 
Calculations were performed using a custom script in MATLAB (MathWorks). 
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Several CFC-assisted ablations were also delivered within the RA and LA to ensure the 
delivery of power did not affect the performance of the CFC. Visual inspection of the 
lesions after the pigs were euthanized was performed only to confirm that power was 
indeed delivered.  
3.2.3 Lesion Formation Under Contact-Force Control 
3.2.3.1 In Vitro Setup 
 
Figure 3.3. Setup for the in vitro ablation experiments. A linear motion 
phantom capable of producing clinically relevant myocardial motion 
moves bovine tissue within a saline bath. The CFC is attached to a force-
sensing ablation catheter and steerable sheath, enabling the delivery of 
RF lesions to moving tissue under force control. 
The impact of the CFC on lesion production was evaluated using an in vitro model 
simulating the beating heart, adapted from the experimental setup and protocol of Shah et 
al. [14]. Illustrated in Figure 3.3, the distal portion of a steerable sheath, housing a force-
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sensing ablation catheter, was deflected 90 and mounted over a Delrin platform 
submerged within an acrylic tank filled with 0.7% saline at room temperature. The platform 
was fixed to a custom-built linear motion stage, which could be raised and lowered by a 
gear motor. An RF generator (EP Shuttle, Stockert GmbH, Munich, Germany) in power-
control mode delivered RF energy between the catheter-tip electrode and a ground plate 
fixed underneath the platform. Slabs of bovine muscle, 20-30 mm thick, were placed on 
the platform. A peristaltic pump (CoolFlow®, Biosense Webster, Irvine, CA) connected to 
the irrigation port of the catheter, delivered 0.7% saline during RF delivery.  
The linear motion phantom was driven in 1 of 2 modes, either reproducing CF 
measurements recorded by force-sensing catheters during RF delivery in patients [23] or 
simulating empirically derived cardiorespiratory motion profiles (Figure 3.4). For the 
simulated motion profiles, the respiratory component resembled typical tidal lung volume 
profiles, while the cardiac component replicated either intermittent or variable contact 
profiles. Simulated cardiac and respiratory motion waveforms with user-defined 
amplitudes and frequencies were used to reproduce scenarios of intermittent catheter-tissue 
contact, induced patient apnea, and various combinations of dominant respiratory or 
cardiac motion. Simulated motion was used to isolate tissue motion, without the 
introduction of artifacts potentially introduced by a physician operation or the force sensor 
itself (e.g., noise). 
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Figure 3.4. Sample CF profiles measured as the linear motion phantom 
moves tissue against a fixed catheter. The CF profiles in A through C 
simulate force generated during patient ablations. The profiles in D 
through F represent examples of simulated profiles: D combination of 
cardiac and respiratory motion (cardiac: 75 BPM, 15 g peak-to-peak; 
respiration: 12 BPM, 30 g peak-to-peak; offset: 10 g), E intermittent 
cardiac motion (cardiac: 75 BPM, 30 g peak-to-peak; respiration: none; 
offset: none), and F variable cardiac motion (cardiac: 75 BPM, 30 g 
peak-to-peak; respiratory: none; offset: 20 g). 
3.2.3.2 Protocol 
RF energy was delivered to the tissue at 20 W for 30 seconds; the irrigation flow rate was 
at 17 ml/min. First, CFC-assisted ablation lesions were delivered to stationary tissue at 4 
force levels (5 g, 15 g, 25 g, and 35 g). These lesions were used as “control lesions” – i.e. 
created in the absence of motion. The same set of ablation protocols was then repeated, but 
the motion stage was set to execute randomly selected motion profiles with the CFC 
enabled to maintain the force constant at 1 of the 4 force levels. Lastly, to mimic lesion 
production during manual intervention, lesions were delivered to moving tissue while the 
CFC was disabled. For all experimental conditions, CF profiles were recorded, and the 
mean, CFV and RSD were calculated. 
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3.2.3.3 Lesion Measurement 
Once lesions were delivered, the tissue slabs were sliced along the centre of each lesion 
using a scalpel to expose the cross-section. Photographs of sectioned lesions were taken 
with a camera mounted in a 3D-printed custom bracket to ensure that the cross-section of 
the lesion was centred and parallel to the aperture of the camera; a constant distance 
between the camera and lesion surface enabled calibration of the images. The photographs 
were randomized prior to analysis by a blinded observer. The dimensions of the necrotic 
zone within each lesion were measured using digital callipers in the image-analysis 
software ImageJ [27]. The maximum diameter, maximum depth, and depth at the 
maximum diameter for each lesion were measured (Figure 3.5). Lesion volumes were 
calculated using the formula for a truncated oblate spheroid: 







where a = Maximum Diameter / 2, c = Maximum Depth - Depth at Maximum Diameter, 
and h = c - Depth at Maximum Diameter. Similar ellipsoidal modelling of lesion volume 
has been used previously [14]. 
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Figure 3.5. Photograph of a cross-section through an ablation lesion 
(left) illustrating the locations where measurements were made in order 
to calculate lesion volume: maximum diameter (Ø); maximum depth 
(D); and depth at maximum diameter (DØ). The truncated oblate spheroid 
approximation (right) was used to measure volume, characterized by 
dimensions a, c, and h. The indentation left by the catheter tip pushing 
into the tissue was included in lesion volume calculation. 
3.2.3.4 Statistical Analysis 
Statistical analysis was performed using Prism 7 (GraphPad Software, USA). Two-way 
analysis of variance (ANOVA) was performed for both lesion volume and lesion depth to 
determine if the set-force level effect on lesion size was statistically significant. Means at 
each set force level were compared and the Sidak multiple comparison test was used to test 
the hypothesis that the volume and depth of CFC-controlled lesions delivered to moving 
tissue do not differ from those of lesions delivered to stationary tissue. A p-value of < 0.05 
was considered statistically significant. 
3.3 Results 
3.3.1 In Vivo Experiments 
Fourteen CF-control experiments were performed, 8 in the LA, 5 in the RA, and 1 in the 
LV. Of these, 12 experiments were performed with the CFC set to repetitive control mode 
using the heart rate determined from ECG and 2 with the CFC set for adaptive control 
mode (the results below are averages of all 14 experiments). Representative examples of 
the CF profiles achieved when using repetitive control and adaptive control are provided 
in Figure 3.6A through Figure 3.6C and Figure 3.6D, respectively. Through manual 
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catheter intervention, the interventionalist was able to maintain an average force level of 
24.6 ± 6.4 g, which was larger than the target of 20 g; the smallest average force was 14.9 
g, and the largest average was 30.5 g. In contrast, for all CFC-assisted interventions, with 
a set force of 20 g, the average CF was 19.9 ± 0.3 g [range 18.9 g to 20.1 g]. When 
compared to manual intervention, CFC-assistance resulted in a reduction in CFV from 31.6 
± 15.9 g to 4.6 ± 1.1 g (p < 0.0001) and RSD from 53 ± 24 % to 20 ± 7 % (p = 0.005). 
 
Figure 3.6. Results from four experiments performed in various 
locations in the LA and RA. Each CF profile begins with manual 
intervention prior to CFC engagement (red line). The regions targeted 
were: LA appendage without A and with apnea B; high RA with apnea 
C while changing the set level of force from 20 g (blue area) to 10 g 
(green area); D while delivering a lesion (red area) to the RA septum. 
The mean CF ± CFV (RSD) during manual and CFC-assisted 
intervention is reported. Note: the CFC was able to compensate for 
myocardial motion greater than that observed in humans (A and B), 
where the CFC was capable of reducing spikes of over 50 g at a heart 
rate over 110 BPM down to negligible disturbances. Note the difference 
in time and force scales. 
Analyzing CFC-assisted performance on a regional level, no significant difference in CFV 
between the LA (4.9 ± 1.2 g, n = 8) and RA (4.0 ± 0.6 g, n = 5) was observed (p = 0.161). 
While testing the CFC in the LV, catheter engagement induced premature ventricular 
contractions (PVC). The presence of PVC caused the repetitive control system to 
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temporally lose synchrony with the cardiac motion of the pig heart, resulting in poor 
performance. In the single case where PVCs were not induced (Figure 3.7), the CFV was 
reduced from 32.9 g to 8.6 g when the CFC was engaged. Importantly, the maximum force 
measured did not exceed 50 g in any of the cases when the CFC was engaged (all three 
chambers) and was lower than the maximum measured during manual intervention. 
 
Figure 3.7. An example experiment of the CFC employed in the LV. 
Interval A reveals significant cardiac motion. Engaging the CFC in 
repetitive control mode (red line) induced PVCs resulting in poor force 
control performance. The CFC was able to resynchronize with the 
heartbeat, likely due to the disappearance of PVCs (blue line), resulting 
in improved control, Interval C. 
3.3.2 Contact-Force Control In Vitro 
The mean, CFV and RSD of the CF profiles recorded during CFC-assisted ablation-lesion 
delivery for the 3 sets of experiments (CFC-assisted lesion delivery to stationary tissue, 
CFC-assisted lesion delivery to moving tissue, and manual lesion delivery to moving 
tissue) are shown in Table 3.1. Similar to the in vivo results, the average CF remained 
within 1 g of the set level, and the CFV reduced to less than 5 g on average for all set levels 
of the CFC. Specifically, CFC-assisted intervention reduced CFV from 19.4 ± 10.2 g to 4.0 
± 1.0 g (p < 0.0001) and RSD from 64 ± 39 % to 25 ± 14 % (p < 0.0001). When setting the 
CFC with a modest set force (15 g and greater), the resulting RSD improved to 17 ± 7 %. 
3.3 Results 86 
 
Versus manual intervention, employing the CFC narrowed the distribution of contact 
forces and centred in on the set force, improving precision and accuracy. Furthermore, the 
range (the difference between maximum and minimum) of contact forces was reduced by 














Stationary Tissue         
5 g 6 4.9 ± 0.03 1.7 ± 0.3 8.2 ± 0.2 6.5 ± 0.4 1.7 ± 0.1 21 ± 1 
15 g 6 14.9 ± 0.02 11.1 ± 0.5 18.9 ± 0.5 7.8 ± 1.0 1.7 ± 0.1 8 ± 0  
25 g 6 24.9 ± 0.03 20.5 ± 0.7 29.4 ± 0.6 8.9 ± 1.2 1.8 ± 0.1 5 ± 0 
35 g 6 34.9 ± 0.03 30.4 ± 1.0 39.8 ± 0.7 9.4 ± 1.4 1.8 ± 0.1 4 ± 1  
Moving Tissue        
CFC-Assisted        
5 g 6 5.1 ± 0.1 -2.8 ± 0.7 13.0 ± 2.0 15.8 ± 2.9 3.0 ± 0.4 47 ± 8 
15 g 9 14.7 ± 0.3 6.4 ± 1.8 26.1 ± 5.0 19.7 ± 6.7 4.1 ± 1.1 22 ± 5 
25 g 6 25.0 ± 0.1 12.2 ± 2.2 39.1 ± 5.1 23.5 ± 2.7 4.7 ± 1.2 19 ± 3 
35 g 7 34.4 ± 0.6 26.6 ± 1.1 44.1 ± 1.0 17.5 ± 1.5 4.1 ± 0.8 9 ± 0 
Manual 15 15.9 ± 7.3 0.02 ± 6.0 42.9 ± 12.0 42.9 ± 13.4 19.4 ± 10.2 64 ± 39 
Table 3.1. Characteristics of CF profiles recorded during CFC-assisted 
and manual ablation delivery. Comparison of generated CF profiles with 
and without (i.e., manual intervention) the CFC on stationary and 
moving tissue. Values are expressed as mean ± standard deviation. Note 
that for manual lesion deliver to moving tissue, there was no desired 
force actively compensated for.  
It is important to note that these results include several ablation experiments performed 
while the motion phantom was driven to reproduce variability that resembles patient, 
catheter, or unpredictable cardiorespiratory motion. Even in these irregular motion cases, 
CFV was reduced to less than 5 g (and RSD to below 30%) when the CFC was used. 
Comparative example force profiles achieved with the CFC when the motion was irregular 
are shown in Figure 3.8. 
87 Eliminating the Effects of Motion during RF Ablation Delivery 
 
 
Figure 3.8. Results from two experiments performed in vitro where the 
phantom was driven to reproduce motion profiles based on force 
measurements obtained from force-sensing catheters during RF delivery 
in patients. The beginning of each experiment shows tissue motion 
characteristic of unpredictable respiration. With the absence of 
significant periodic tissue motion, the adaptive control mode of the CFC 
was engaged (red line) with a set force level of 25 g (left) and 15 g 
(right). Average contact force ± CFV (RSD) are reported. 
3.3.3 Lesion Production With and Without Force Control 
Representative example photographs of cross-sections of delivered lesions are provided in 
Figure 3.9. The measured depths and calculated volumes of the CFC-assisted ablation 
lesions on stationary and moving tissue, as well as lesions delivered to mimic manual 
intervention (without the CFC), are presented in Figure 3.10. As determined by two-way 
ANOVA, statistically significant differences were observed between lesion depth and 
volume for lesions delivered to stationary or moving tissues at different set force levels (p 
< 0.0001). Most importantly, motion during lesion delivery (while employing the CFC) 
had no effect on lesion depth or volume (p = 0.82 and 0.78, respectively) compared to 
stationary lesions. On the other hand, manual intervention delivered to moving tissue 
resulted in highly inconsistent lesion depth and volume. Multiple comparison analysis 
revealed a small difference in lesion depth (not volume) between stationary and moving 
tissue when the set level was 5 g. 
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Figure 3.9. Photographs of the cross-sections of delivered ablation 
lesions to moving tissue. Representative examples of ablation sizes while 
the CFC is disabled, representing manual intervention, and while the 
CFC is set to desired forces of 5 g, 15 g, 25 g, and 35 g (organized in 
columns). Lesions delivered during manual intervention vary in size, 
while prescribed CFC-assisted ablation lesions are precise and 
reproducible, despite myocardial motion. 
 
Figure 3.10. Measured lesion depth and volume are presented for CFC-
assisted lesion creation on stationary tissue (A and D) and on moving 
tissue (B and E). For comparison depth and volume are also presented in 
panels C and F for lesions created under manual intervention (i.e. no 
control); these lesions were generated while the phantom was moving 
with the same motion profile as the controlled lesions generated in B and 
E. For the same set force, no statistical differences between lesions 
volumes delivered to moving tissue and lesions delivered to stationary 
tissue were observed. Note that retrospectively analyzed average force 
values for the manually delivered ablations (C and F) demonstrated a 
similar relationship between depth/volume and achieved contact force, 
as expected; however, unlike the CFC-assisted case, the force level could 
not be set prospectively by the operator. 
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3.4 Discussion 
In this study we demonstrated that: a) on average, the CFC can consistently control force 
to within 1 g of the set level; b) the variation in contact force dropped below 5 g when 
using the CFC – a 5-fold improvement over manual intervention; c) when using the CFC, 
the catheter tip never lost contact with the tissue and never approached dangerous force 
levels; d) delivered ablation lesions were reproducible regardless of myocardial motion, 
and finally, e) delivered lesions to moving tissue were of the same depth and volume as 
lesions delivered in the absence of tissue motion. Recalling the clinical studies performed 
by Ullah et al. [17] and Makimoto et al. [18], which respectively report that a CFV of less 
than 5 g ensures a maximum impedance drop and RSD less than 30% is correlated with 
more durable lesions, our results suggest that using the CFC can assist clinicians in 
achieving these previously unattainable goals.  
During the in vitro ablation experiments, on average a 2-fold reduction was observed 
between the standard deviations of lesion volume (and depth) of CFC-assisted and 
manually delivered lesions. This indicates improved precision and accuracy in lesion 
production over manual intervention while the tissue was moving. More importantly, 
regardless of tissue motion, lesions delivered were reproducible and statistically identical 
in size compared to lesions delivered to stationary tissue, indicating that lesions were 
delivered to moving tissue as if no motion was present. The slightly significant difference 
in lesion depth noted at the 5-g level is attributed to the likelihood that at low force levels, 
lesion production is more vulnerable to variation in force – improving the control 
performance of the CFC may prevent this. 
During in vivo evaluation in the porcine model, the CFC demonstrated the ability to 
compensate for significant cardiac tissue motion, greater than those observed in humans. 
The CFC was capable of reducing spikes of 50 g caused by the systolic-diastolic motion of 
the heart at over 110 BPM to negligible disturbances (Figure 3.6A and Figure 3.6B). This 
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performance was achieved in all target locations in the LA and RA. However, in the LV, 
we observed poorer performance, likely due to the occurrences of PVCs and the fact that 
the repetitive controller was optimized for atrial use. Further development of the CFC 
control system, which may involve fine-tuning of the repetitive controller or utilizing the 
adaptive controller, is required before a more extensive evaluation in the LV. 
A primary concern of using the CFC is the possibility of perforating the tissue while the 
CFC is engaged. For this reason, the CFC is programmed to continuously monitor contact 
force and automatically retract the catheter back into the sheath and disable the force 
control algorithm if the force level exceeds a user-defined limit of 80 g. It is important to 
note that for all CFC-interventions performed during the in vivo and in vitro experiments, 
the force never exceeded 50 g. Demonstrated in Chapter 2, the CFC has shown to 
effectively react to large and sudden changes in tissue displacement that would otherwise 
result in large spikes of contact force and potentially cause tissue damage. 
The development of two different control systems (adaptive and repetitive) was required 
to handle types of motion typically observed during patient therapy. Different controllers 
were required to compensate for the delay, sampling rate and noise characteristics of the 
force sensor incorporated on the catheter tip. The repetitive control system can be used to 
eliminate fast systolo-diastolic force variations when they are the most dominant 
component, but strictly requires that tissue motion is periodic (i.e. normal sinus rhythm). 
The current version of the repetitive control system is unable to effectively handle the non-
periodic disturbances observed in patients in AF or instances of mechanically-induced 
PVCs but was able to compensate for motion associated with heart-rate drifts up to ± 7%. 
On the other hand, the adaptive control system ignores fast disturbances caused by cardiac 
motion and can only reject gradual changes in force variations and is suitable for most 
interventions where the largest motions are caused by respiration or involuntary movement. 
The adaptive controller may, therefore, be ideally suited for use during arrhythmias, where 
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cardiac-induced motion is expected to be smaller. Lastly, in the cases where both cardiac 
and respiratory motion is large, both control algorithms will have reduced benefit; 
however, such cases are rare. 
The benefit of the CFC is dependent on the angle between the catheter tip and the surface 
of the tissue, with the highest improvement achieved during perpendicular contact, when 
the effect of motion is greatest. On the other hand, when the catheter is nearly parallel to 
the tissue, such as during CTI ablation, the CFC is expected to have little benefit. In this 
study, the CFC was evaluated at angles up to 45°; however, a significant reduction of force 
variability has been observed at angles as large 60° from the normal (data not shown). 
Additional studies are required to determine a threshold angle beyond which using the CFC 
will not provide benefit. 
Systolo-diastolic cardiac motion and respiration are the primary contributors to variability 
in contact force [19, 21, 28]. Clinical techniques used to mitigate their effect include rapid 
atrial pacing, high-frequency jet ventilation (HFJV), and induced apnea [28-33]. Rapid 
pacing has been shown to reduce the standard deviation in force by less than 1 g compared 
to its non-paced counterpart, and its effectiveness is dependent on regional anatomical 
location within the LA [29]. In a study examining almost 30,000 RF applications, HFJV 
only reduced force variability index by 0.06 on average in comparison to normal ventilation 
[33]. In contrast, to achieve optimal force variability based on the variability criteria of 
CFV (less than 5 g [17]) and RSD (less than 30% [18]), the CFC reduced standard deviation 
in the force profiles by 6.3 g on average and the force variability index by 0.21. Importantly, 
the CFC is a device that can be used independently to compensate for the effect of motion 
or to supplement one of these techniques. In particular, the combination of induced apnea 
and the CFC working in repetitive-control mode would be an extremely effective way to 
control force (Figure 3.6B). 
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Emerging catheter ablation techniques in treating AF include delivering RF energy with 
high-power (typically 70-90 W) for 4-8 seconds. In pre-clinical porcine studies, high-
power short-duration (HP-SD) ablation have been shown to successfully isolate the 
pulmonary veins [34, 35]. However, in these studies, HP-SD in swine have demonstrated 
that CF values between 10 g and 20 g resulted in successful ablation [34] while fluctuating 
forces exceeding 40 g caused steam pops [35]. For clinical applications of HP-SD, the EP 
would need to maintain CF within the guidelines set out by these studies, which may be 
difficult to achieve reliably. These preclinical studies indicate the importance of controlling 
CF and minimizing variability, regardless of the method of RF delivery. Further studies 
evaluating the role of CF variability in HP-SD lesion production is needed. 
3.5 Study Limitations 
While the study demonstrates that the CFC can reduce the effects of motion on contact 
force during ablations in vivo and in vitro in a limited set of experiments, more 
comprehensive studies of the device are required (e.g. in the LV) before the real impact of 
using the CFC can be determined. 
Typical CF profiles observed in the clinical setting are dominated by respiration; CF 
disturbances caused by cardiac motion are often negligible in most targets. Surprisingly, 
the opposite relationship was observed in the porcine model, where for most target 
locations, disturbances were dominated by systolo-diastolic cardiac motion, while 
disturbances caused by respiration were smaller in comparison. As a result, the primary 
control mode that was tested in vivo was the repetitive control system. While the adaptive 
control system could not be extensively evaluated in vivo, this control mode was 
thoroughly tested in the in vitro experiments. 
Lesion production in the in vitro study does not directly reflect lesion production in 
humans. Our experimental set up did not mimic blood and tissue temperature and did not 
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model convective and perfusive cooling. However, all experimental conditions remained 
consistent from lesion-to-lesion, and the results generated from these experiments were 
solely dependent on tissue motion and CF. The measured reference impedance (75-85 Ω, 
achieved by titrating the salinity to 0.7%) was low compared to clinical levels but was 
chosen to enable the generation of measurable lesions at clinically relevant CF levels and 
duration. Finally, lesion volume was measured only by a single observer and was based on 
measurements of the necrotic area. Systematic bias was avoided by cropping, anonymizing, 
and randomizing the photographed tissue samples, thereby blinding the observer to the 
ablation protocol used for each lesion. 
3.6 Conclusions 
Monitoring catheter-tissue force has become an important tool for RF catheter ablation in 
patients and has become a standard-of-care. Until this work, CF information has been 
strictly used for visual guidance and navigation. The CFC uses this available information 
and optimizes lesion production on moving tissue by controlling catheter-tissue CF. In this 
study, we demonstrated the ability for the CFC to significantly improve catheter-tissue CF 
profiles and their impact on lesion production in moving tissue. The results obtained in this 
study suggest that the CFC can be a valuable add-on tool available to electrophysiologists 
to optimize lesion delivery techniques and ultimately improve patient outcomes. 
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4 Remote Catheter Navigation and Contact-
Force Control 
This chapter is adapted from “Remote Catheter Navigation and Contact-Force Control: 
Design and Evaluation of a Novel Steerable Sheath and Catheter Robotic Navigation 
System.”3 
My contribution to this chapter involved (i) designing and developing all components of 
the robotic navigation system, (ii) designing and developing phantoms, (iii) preparation 
and conducting experiments, (iv) collecting and analyzing data, and (v) writing 
manuscripts. 
4.1 Introduction 
Radiofrequency (RF) catheter ablation is a widely used therapy to permanently treat atrial 
fibrillation (AF) – the most common form of cardiac arrhythmia. Delivering contiguous 
transmural ablation lesions is crucial for improving clinical outcomes by increasing first-
procedure efficacy rates [1]. Unfortunately, 40% to 70% of patients experience a 
recurrence of AF symptoms due to electrical reconnections of isolated pulmonary veins [2-
                                                           
3
Gelman D, Skanes AC, Drangova M. “Remote Catheter Navigation and Contact-Force Control: Design 
and Evaluation of a Novel Steerable Sheath and Catheter Robotic Navigation System,” IEEE Transactions 
on Biomedical Engineering (In Preparation).  
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4]. AF ablation strategies are complex, technically challenging, require a high degree of 
dexterity and physical effort. 
To this end, over the past two decades, three remote catheter navigation systems (both 
robotic [RNS] and magnetic navigation systems [MNS]) have been developed, approved 
by the FDA, and introduced clinically. The Amigo™ RNS developed by Catheter Precision 
facilitates control of a single conventional ablation catheter by loading it into an 
electromechanical manipulator providing full-range of its functions (insertion, withdrawal, 
deflection, and rotation) operated by a hand-held remote. However, the system lacks a 
steerable sheath, thereby significantly reducing the degrees-of-freedom (DOF) associated 
with catheter manipulation. Steerable sheaths are widely used as they improve 
maneuverability, stability, and catheter-tissue contact, collectively resulting in better 
clinical outcome [5-8]. The Sensei® X RNS developed by Hansen Medical (acquired by 
Auris Health), solves this problem by robotically steering two concentric sheaths, through 
which any catheter can be introduced. The entire assembly is manipulated within the heart 
using pull-wires actuated by a robotic arm controlled by a 3D joystick [9]. Early reports of 
high incidence of clinical complication, steep learning curve, and the inability to navigate 
within the left ventricle and the coronary sinus due to the large 14 Fr outer sheath are 
reported shortcomings of this system [9-12]. Lastly, the NIOBE® MNS developed by 
Stereotaxis uses a specialized magnetic catheter, which can be navigated to target locations 
by changing the orientation of two permanent magnets positioned on each side of the 
patient’s body. The weak magnetic field (0.08 T) and flexible catheter ensures a safe 
procedure. However, it results in relatively low catheter-tissue contact force, which is 
associated with ineffective lesion production and increased rates of AF recurrence [13-16]. 
The magnetic catheter is not responsive in real-time as motions require mechanical 
movement of external magnets followed by electromechanical actuation. However, the 
primary shortcoming among MNS is the inability of the magnetic catheter to detect real-
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time catheter-tissue contact force used clinically to guide and assess lesion deliver in real-
time. Robotic and magnetic navigation systems have shown to reduce radiation exposure, 
physician exhaustion, and RF duration [17]. However, none of these systems has 
demonstrated better clinical outcome versus the manual catheter intervention, and the 
potential advantages of these systems are offset by additional costs for the systems itself, 
consumables and maintenance contracts. Emerging technologies must not only provide the 
ability to precisely place lesions but also optimize lesion production.  
Among all factors that influence lesion production, the catheter-tissue contact force (CF) 
is one of the most critical [18-21]. As such, the incorporation of novel force-sensing 
ablation catheters into standard practice has become the cornerstone for RF ablation 
therapy, as it has demonstrated improved clinical outcome [22-24]. Higher levels of force, 
although delivering larger lesions, can result in tissue perforation, intramural boiling, and 
collateral tissue damage [20, 25-28]. Lesions delivered with insufficient force produce 
ineffective superficial lesions [16] and have a higher risk of intermittent contact [29]. 
Recent literature also highlights the importance of CF variability on lesion production, not 
merely just CF quantity [21, 30, 31]. Unfortunately, current tools and techniques to 
improve the stability of CF are limited and reliably achieving an optimal CF profile is 
virtually impossible. 
Our group has developed a novel RNS, enabling remote navigation of a conventional 
steerable sheath and force-sensing ablation catheter. The Steerable Sheath and Catheter 
Robotic Navigation System (SSC-RNS) allows for full-range manipulation of a 
conventional steerable sheath (insertion, withdrawal, rotation, and deflection) in 3-DOF, 
as well as insertion and withdrawal of a force-sensing ablation catheter within the sheath 
in 1-DOF. The 4-DOF SSC-RNS also incorporates a catheter contact-force controller – a 
compact device, which has been independently evaluated previously [32, 33]. The force 
controller improves the catheter-tissue CF profile and can deliver optimal and reproducible 
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ablation lesions, even in the presence of cardiac tissue motion. The device maintains an 
average CF to within 1 gram (g) of the set level and reduces CF variability to less than 5 
grams – a variability considered optimal for lesion production [31]. 
The purpose of this study is to evaluate the SSC-RNS ability to enable remote navigation 
of a force-sensing ablation catheter. First, to evaluate the performance of the SSC-RNS, an 
electromagnetic tracking system was used to track the input device and the catheter tip 
during dynamic motion. Second, an in vitro contractile bench model representing a cardiac 
chamber was used to test the hypothesis that the SSC-RNS can navigate a catheter to 
specific target locations under the control of a skilled electrophysiologist (EP) and maintain 
a set amount of force on moving tissue-mimicking material, despite the presence of 
cardiorespiratory motion. 
4.2 Steerable Sheath and Catheter Robotic Navigation 
System 
The SSC-RNS comprises three distinct components: an intuitive master input device, 
where the EP interfaces to control the robotic system, a robotic system, which is 
responsible for positioning the catheter and sheath according to the changes in motion of 
the input device, and finally, the catheter contact-force controller – a device incorporated 
within the robotic system – which employs closed-loop CF control between the catheter 
tip and moving tissue.  
4.2.1 Master Input Device 
The input device to the SSC-RNS, which has been validated in previous work [34], 
provides an interface to the user to control the robotic system. The input device embodies 
a repurposed steerable sheath handle (Agilis™ NxT, Abbott Laboratories, St. Paul, MN) 
fitted with 3D-printed inserts that extend to support walls mounted with two optical 
encoders (Figure 4.1). One optical encoder (HEDS 5600, Infineon Technologies, 
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Neubiberg, Germany) detects the rotation of the sheath handle, and another encoder is used 
to detect the deflection mechanism of the sheath. The entire assembly is then mounted on 
a linear rail fitted with a rack, where a third encoder coupled to a pinion detects insertion 
and withdrawal of the sheath handle. 
 
Figure 4.1. Photograph of the input device to the robotic system A. 
Three optical encoders (blue arrows) detect all motion from a steerable 
sheath handle (insertion, withdrawal, rotation, and deflection indicated 
by yellow arrows). A digital user interface programmed with a menu 
system provides the user full control of all features of the robotic system 
B. 
A microcontroller-powered (Teensy, PJRC, Sherwood, OR) electronics system, mounted 
onto the assembly, is responsible for quadrature encoding and transmitting the position 
information to the robotic system using a wireless transceiver (XBee, Digi International, 
Minnetonka, MN). The electronics also provide a digital user interface (LCD with tactile 
buttons), which allows the EP to set parameters of the SSC-RNS including: inserting and 
withdrawing the catheter through the sheath; setting robotic motion scaling; disabling the 
input device, and home the robotic system (Figure 4.1B). Importantly, the interface allows 
the user to configure the parameters for the force controller including setting the desired 
level of force and force-time integral (a metric used in the clinic to access lesion 
production) and other parameters such as cardiac or respiratory gating. 
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4.2.2 Robotic System 
 
Figure 4.2. The robotic system takes the form of a cylindrical gantry, 
which opens along its long axis, A. Within the gantry; battery-powered 
electronics receive position data from the input device to insert and 
withdraw the catheter and sheath as well as deflect the sheath tip using a 
deflection mechanism (indicated with yellow arrows). The electronics 
also receives force information and processes a control algorithm to 
drive the force controller. While in a closed position, the gantry sits on 
two pairs of rollers driven by a DC motor affixed to the back of the unit, 
B. A separate electronics control system received rotational position data 
from the input device to rotate the catheter and sheath. 
The robotic system (Figure 4.2) incorporates a cylindrical gantry with hinges allowing it 
to open up along its long axis. Within the gantry, two carriages sitting on linear guide rail 
are driven by a lead screw mechanism coupled to a DC motor (9.7:1 25D Gearmotor, 
Pololu, Las Vegas, NV). One of the carriages houses a sprocket and chain mechanism 
powered by another DC motor (47:1 25D Gearmotor, Pololu, Las Vegas, NV) designed to 
actuate the deflection mechanism of the sheath handle. An electronic control system and 
battery are mounted within the gantry. An ARM-based microcontroller (Arduino Due, 
Arduino, Turin, Italy) uses a wireless transceiver to receive position data from the input 
device and process two proportional-integral (PI) controllers: 1) to control the lead screw 
mechanism resulting insertion and withdrawal the catheter and steerable sheath; and 2) to 
control the deflection mechanism to deflect the tip of the steerable sheath. Generated pulse-
width modulated (PWM) control signals are received and amplified by motor drivers 
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(VNH5019 Motor Driver Carrier, Pololu, Las Vegas, NV) before driving each 
corresponding motor. 
While in a closed position, the gantry sits securely on two pairs of rollers, which are driven 
by a final DC motor (131:1 37D Gearmotor, Pololu, Las Vegas, NV) affixed on the back 
of the unit (Figure 4.2B). An electronic control system receives wireless position data from 
the input device and processes a PI control algorithm to generate a PWM signal. The 
control signal is then received and amplified by a motor driver, resulting in rotational 
tracking of the sheath and catheter. The robotic system measures approximately 86 cm 
long, 16 cm wide, and 20 cm tall. 
4.2.3 Catheter Contact-Force Control 
The force controller is an independent compact device, which monitors real-time CF 
measurements and autonomously adjusts the position of a force-sensing ablation catheter 
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) within a steerable 
sheath thereby maintaining the force level set by the EP. The device, described in detail in 
Chapter 2 and Chapter 3, is clamped onto the back-end of a steerable sheath (Agilis™ NxT, 
Abbott Laboratories, Chicago, IL) near the hemostatic seal; a linear DC servomotor (LM 
2070, MICROMO, Clearwater, FL) clamped onto the catheter shaft via a locking adaptor 
adjusts catheter motion with respect to the sheath (Figure 4.3). The force-sensing catheter, 
steerable sheath and contact-force control device are placed and secured onto the two 
carriages within the gantry of the SSC-RNS. The electronics control system (within the 
gantry) receives real-time CF measurements transmitted by a separate microelectronics 
system; this stand-alone system receives, parses, and transmits incoming force information 
through a local area network connection with a research-based catheter mapping system 
(CARTO® 3, Biosense Webster, Irvine, CA). The SSC-RNS electronics process a control 
algorithm and generate a PWM signal, which sent to a separate motor controller and driver 
(MCLM 3003, MICROMO, Clearwater, FL). The signal directly adjusts the catheter 
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position within the sheath to maintain constant force at the catheter tip under closed-loop 
control. The force controller of the SSC-RNS uses similar control algorithms described in 
Appendix C. 
 
Figure 4.3. Line drawing A and photograph B of the force controller 
attached to a force-sensing ablation catheter and steerable sheath. A 
locking adaptor clamps the catheter to a linear actuator (shown in B), 
which enables the catheter to be inserted and withdrawn within the 
sheath. 
4.3 Evaluation 
4.3.1 SSC-RNS Catheter Positioning 
Prior to performing in vitro evaluation of the system, the tracking performance of the SSC-
RNS was quantified using an electromagnetic tracking system (Aurora®, Northern Digital, 
Waterloo, ON, Canada). An electromagnetic field generator captured the location of a 5-
DOF sensor, which was fed through the steerable sheath to the distal tip (in place of the 
catheter). A second 5-DOF sensor was fixed to the repurposed sheath handle of the input 
device. A series of six 10-second dynamic motion profiles were performed on the input 
device (three insertion and withdrawal, three rotation) and mimicked by the robotic system; 
position coordinates of both sensors were recorded in real-time. Root-mean-squared error 
(RMSE) with respect to the reference position and angle of the input device was calculated. 
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Additionally, steady-state error and lag between the input device and the robotic system 
were determined.  
4.3.2 In Vitro Experimental Setup 
A lab-bench motion phantom representing a beating heart was designed and developed 
(Figure 4.4). The phantom comprises a 60-cm long Tygon tube, which enters a 3D-printed 
hollow truncated 10-cm diameter sphere with 18 6-mm diameter divots scattered on the 
outside of the shell. The opening of the stationary sphere leads to a frame affixed to the 
linear motion stage, which was driven to reproduce cardiorespiratory motion. To mimic 
tissue compliance, a rubber sheet was stretched within the frame. Described in detail in our 
previous work, the linear stage can reproduce both cardiac and respiratory motion, whereby 
the frequency and relative amplitude of each component is user-defined [33]. 
The phantom was scanned using a mobile CT scanner (O-Arm™ 1000 Imaging System, 
Medtronic, Littleton, MA) and the volume image was imported into the catheter mapping 
system (CARTO® 3, Biosense Webster, Irvine, CA). A force-sensing ablation catheter 
(THERMOCOOL® SMARTTOUCH™, Biosense Webster, Irvine, CA) was manually 
placed within the centre of five divots on the outside of the phantom, enabling a five-point 
landmark registration to be performed to register the phantom to the reference coordinates 
of the catheter mapping system. The coordinates of the remaining divots were then 
acquired in the same way – these points represent the “target locations.” 
4.3 Evaluation 106 
 
 
Figure 4.4. Photograph (top-down perspective) of the in vitro motion 
phantom representing a beating heart chamber A. The phantom was CT-
scanned and imported into the catheter mapping system B, where the 
phantom was registered, and target location (white spheres) were 
acquired. B shows the catheter (green arrows) inside the phantom in 
contact with a rubber sheet mounted on a moving wall resulting in a CF 
profile (green square) due to the cardiorespiratory motion reproduced by 
the linear motion stage. 
4.3.3 In Vitro Protocol 
Comparison between manual and remote navigation was performed. A skilled EP (A.C.S.) 
was instructed to navigate a catheter tip (in conjunction with a steerable sheath) to eight 
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stationary target locations using traditional catheter manual intervention. The EP 
manipulated the catheter to each target location between two and six times, resulting in 27 
total navigational tasks. Once the EP reached each target location, the final position of the 
catheter tip was acquired, and the duration of the task was recorded. Between each task, 
the catheter was retracted back to the starting position within the Tygon tubing.  
The EP was then instructed to navigate to two targets on the moving wall – one with a 90° 
catheter-rubber incidence angle and the other with a 45° angle. The linear stage was 
programmed to execute cardiorespiratory motion with randomly selected but clinically 
relevant amplitudes and frequencies for both cardiac and respiratory components. The EP 
was instructed to maintain 15 g of CF between the catheter tip and moving wall for 30 
seconds; the resulting CF profile was recorded. This was repeated three times, each with 
the linear motion stage set to different cardiorespiratory motion parameters. 
The above protocol was repeated by the same EP using the SSC-RNS. The EP was given 
a brief introduction to the user interface of the input device and 5-10 minutes of training. 
The operator was encouraged to use all functions of the SSC-RNS such as catheter insertion 
and withdrawal within the sheath as well as robotic motion scaling. The EP robotically 
manipulated the remote catheter to the same eight stationary targets between one and three 
times, resulting in 22 total navigational tasks (Figure 4.5). During robotically assisted CF 
control experiments on moving targets, the EP was instructed to use to the input device to 
employ the force controller set for 15 g of force. 
The coordinates of the final catheter tip position and their corresponding target location 
were exported from the catheter mapping system, and the relative distance between those 
coordinates was calculated. It is important to note that 0.635 mm separate the inner wall of 
the phantom from the acquired target locations (center of the divot); this value was 
subtracted from each distance measurement. Distances achieved, duration of each task, and 
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recorded CF profiles using manual and robotically assisted intervention were compared 
with one another using a paired t-test to determine significance. The overall interaction 
time by the EP with the SSC-RNS was also recorded. 
 
Figure 4.5. Photograph of the electrophysiologist using the SSC-RNS to 
navigate a remote catheter tip within the in vitro phantom A. The catheter 
tip (green arrow), stationary target locations (white spheres), and final 
catheter tip position (red spheres) are captured and recorded by the 
catheter mapping system B. 
In this study, contact-force variability (CFV) was defined as the difference between the 
mean trough and peak forces. CFV of less than 5 g significantly increased impedance drops 
and achieved higher maximums compared to lesions with greater variation [31]. Other 
metrics have previously been shown to be important for lesion delivery [31, 35, 36]. 
Specifically, the relative standard deviation (RSD) [36] or the coefficient of variation, 
defined as the ratio between the standard deviation of CF to its mean. RSD less than 30% 
(e.g. 10 ± 3 g or 20 ± 6 g) correlated with a reduction in reconnection gaps during PVI [36]. 
CFV and RSD were calculated using a custom script in MATLAB (MathWorks, Natick, 
MA). 
Statistical analysis was performed using Prism 8 (GraphPad Software, San Diego, CA). 
Two-way analysis of variance (ANOVA) was performed to determine if the intervention 
method (manual or SSC-RNS) and catheter angle (90° or 45°) had a significant effect on 
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the force profile. The average CF, CFV and RSD were compared and the Sidak multiple 
comparison test was used to test the hypothesis that robotically assisted intervention 
resulted in improved force profile that is independent of catheter angle. A p-value of less 
than 0.05 was considered statistically significant. 
4.4 Results 
4.4.1 SSC-RNS Tracking Performance 
The SSC-RNS is capable of accurately navigating a catheter remotely, with the following 
specification. While dynamically inserting and withdrawing the catheter and sheath, the 
steady-state error of 0.5 ± 0.4 mm, RMSE of 1.53 ± 0.25 mm and a lag of 24 ± 6 ms was 
observed. While rotating the catheter and sheath, the steady-state error was 2.2 ± 1.9°, 
RMSE of 7.54 ± 0.27° and lag of 63 ± 12 ms (Figure 4.6). 
 
Figure 4.6. Example experiments demonstrating the tracking 
performance of the SSC-RNS. A illustrates the insertion and withdrawal 
of the input device (blue) and corresponding motion of the sheath tip 
(red), resulting in a minimal error. B illustrates rotational tracking and 
error. 
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4.4.2 Catheter Navigation and Contact-Force Control In Vitro 
All navigation tasks were performed successfully. During manual catheter navigation, the 
EP was an average distance of 2.5 ± 0.9 mm from the target location and took 28.7 ± 9.9 
seconds to complete each task. In contrast, while using the SSC-RNS, the EP was an 
average distance of 1.7 ± 0.8 mm from the target location and required 53.1 ± 19.3 seconds 
to complete each task (Figure 4.7). There was a significant difference in the distances to 
the corresponding targets achieved (p = 0.003) as well as the time duration to accomplish 
navigational tasks (p < 0.0001) between manual and robotic intervention. These results 
suggest that there is a higher level of accuracy when using the SSC-RNS over the manual 
approach. Including instruction to the SSC-RNS and performing all navigation tasks, the 
EP’s interaction time with the SSC-RNS was approximately 63 minutes. 
 
Figure 4.7. Distances between target locations and the catheter tip 
position A and their task durations B using manual (n = 27) and robotic 
intervention (n = 22). Within an hour of using the SSC-RNS, the EP was 
completing tasks in a time comparable to the manual approach. 
Through manual catheter invention, the EP was able to maintain an average force level of 
16.8 ± 3.9 g. In contrast, for all robotically assisted interventions, with a set force of 15 g, 
the average CF was 14.9 ± 0.2 g (p = 0.1919) (Figure 4.8). Robotically assisted force 
control resulted in a reduction in CFV from 19.6 ± 11.2 g to 4.7 ± 1.9 g (p = 0.0024), and 
RSD from 48 ± 20 % to 26 ± 3 % (p = 0.007). The above results represent the average of 
four experiments performed with the contact-force controller set to cardiac gating and four 
experiments set to respiratory gating. 
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Figure 4.8. Results from three pairs of experiments, each performed with 
a different motion profile programmed into the linear motion stage. A, 
C, and E illustrates the resulting CF profile using the manual approach. 
Respectively, B, D, and F are the resulting CF profile using the force 
controller of the SSC-RNS. The linear motion stage was programmed 
with dominant cardiac motion, A and B, dominant respiratory motion, C 
and D, and typical cardiorespiratory motion combining both 
components, E and F. For all experiments, the force controller of the 
SSC-RNS was set for 15 grams of force (red line). Average CF ± CFV 
(RSD) is provided for each experiment. 
With a 90° catheter-rubber incidence angle, throughout manual catheter intervention the 
EP achieved an average CF of 19.5 ± 3.7 g; larger than the target force level of 15 g. When 
the incidence angle was reduced to 45° the average force improved to 14.2 ± 1.6 g (p = 
0.013), demonstrating better force control to the desired 15 g level. Importantly, by 
reducing incidence angle the EP was able to significantly reduce CFV from 28.5 ± 8.3 g to 
10.7 ± 3.5 g (p = 0.0011), and RSD from 63.0 ± 10.7 % to 33.8 ± 15.8 % (p = 0.006). In 
contrast, during robotically assisted catheter intervention, no significant difference in 
average CF between incidence angles of 90° (14.9 ± 0.2 g) and 45° (15.0 ± 0.2 g) was 
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measured (p > 0.999). Similarly, there was no significant difference in CFV [90°: 4.7 ± 1.9 
g, 45°: 4.8 ± 2.3 g, p > 0.999] and RSD [90°: 26.3 ± 2.6 %, 45°: 25.8 ± 3.5 %, p > 0.999] 
(Figure 4.9). Unlike manual catheter intervention, robotically assisted force control was 
not dependent on catheter incidence angle; consistent average CF at the set level, and 
reduced CFV and RSD, regardless of the angle tested. 
 
Figure 4.9. Comparison of force profiles while the catheter-rubber 
incidence angle is reduced from 90° (perpendicular) to 45°. Manual and 
robotically assisted catheter intervention are reported. Manual catheter 
intervention resulted in a slight improvement in the force profile. Using 
the SSC-RNS ensured the average force maintained to 15 g set level (left, 
red line), reduced CFV to less than 5 g (middle, red area) and RSD to 
less than 30 % (right, red area), regardless of catheter angle. 
Results comparing the force control performance of the SSC-RNS in vitro with its 
simulation is provided in Appendix E. 
4.5 Discussion 
The design, development and evaluation of a novel robotic platform permitting remote 
navigation of a conventional steerable sheath and catheter and enabling catheter-tissue CF 
control was presented in this study. First, the tracking performance of the steerable sheath 
and catheter robotic navigation system was validated using an electromagnetic tracking 
system. Second, the SSC-RNS was also tested by a skilled operator using an in vitro model 
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representing a beating cardiac chamber. We demonstrated that the robotic system could 
track the input device as well as enabling remote navigation of a steerable sheath and 
catheter, while also providing the capability of maintaining a set force level between the 
catheter tip and moving tissue-mimicking material. 
Measured steady-state errors using SSC-RNS to track the input device were minimal, and 
the lag between the input device and robotic system was negligible (average delay found 
to be no greater than 63 ± 12 ms). During the in vitro experiment, the EP was able to 
successfully reach all target locations using the robotic system with an accuracy 
significantly better in comparison to manual catheter intervention. Furthermore, the robotic 
system provides the ability to control catheter-tissue CF – a task virtually impossible to 
accomplish with manual the approach. The force control performance of the robotic system 
was similar to the results obtained in our previous work, where we evaluated the device 
independent from the SSC-RNS [32, 33]. Similar to the results discussed in detail in 
Chapter 3, force control of the SSC-RNS ensured that the average force is less than 1 g of 
the set level. Under force control, RSD reduced to less than 30% on average, implying 
more durable lesion delivery would occur in the clinic, according to Makimoto et al. [36]. 
CFV reduced to less than 5 g, implying that the force controller of the SSC-RNS would 
provide improved durability in PVI, according to Ullah et al. [31].  
During manual catheter intervention, as demonstrated in this study, the EP can improve the 
CF profile by reducing the catheter-tissue incidence angle. The shallower incidence angle 
allows the distal catheter tip to deflect along with the displacement of tissue in a spring-
like fashion. Achieving a shallow angle is often not possible, and controlling the amount 
of average CF is limited in this orientation [37]. Importantly, deeper lesions are achieved 
when the catheter tip is perpendicular to the tissue (i.e. 90° incidence angle) [38]. However, 
as demonstrated in this study, perpendicular orientation results in more CF instability. 
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Unlike the manual approach, robotically assisted force control ensured that the CF profile 
is optimal and independent of catheter incident angle. 
One of the features of the SSC-RNS includes robotic motion scaling. This feature allows 
scaling of the motion of the robotic system in relation to the input device. For instance, if 
a motion scaling setting of four were to be used, an advancement of the input device of 10 
cm would result in 2.5 cm advancement of the remote catheter and sheath; the same 
principle is applied for rotation and deflection. During the experiments, the EP robotically 
guided the catheter to the general area of the target location, then enabled motion scaling 
(set to two) to adjust the catheter tip position to the target location finely; the EP found this 
feature to be very useful in getting the catheter tip closer to target. The authors suspect this 
contributed to the improved accuracy in comparison to manual catheter intervention. 
The EP acknowledged that the robotic system greatly enhanced the stability of the catheter. 
Since the SSC-RNS always holds the remote catheter and sheath, it allows the EP to focus 
on slight adjustments to hit the target location – this implies that the robotic system would 
be ideal for line or “drag” ablation strategies. Furthermore, engaging the force controller 
without the need of manually holding the catheter and sheath position throughout an RF 
application (30-60 seconds) is a considerable advantage over the manual approach as it 
improves catheter stability and reduces operator fatigue. 
Through formative studies our group performed prior to this study, the majority of EPs 
manipulate the steerable sheath to guide the catheter tip to a target and dial in the force by 
advancing or retracting the catheter within the sheath. The operator involved in this study 
manipulated the instruments differently, whereby the catheter (rather than the sheath) is 
manipulated for most of the procedure. The SSC-RNS was designed for operators who use 
the former strategy. Because the EP interacted with the SSC-RNS for approximately an 
hour, the amount of time required to complete each navigational task remotely was greater 
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than that required for manual intervention. However, it is expected that subsequent 
sessions, with minimal additional practice, would result in faster navigation times. 
Additional studies with multiple users need to be performed to evaluate the learning curve 
of the SSC-RNS. We suspect that other EPs who use the former strategy would require less 
training due to the intuitive input device and the principal design of the SSC-RNS. A 
primary limitation in this work is that only one EP was involved in this study. Involving 
more operators, particularly EPs who manipulate the steerable sheath and catheter using 
the former strategy, may affect the reported results. 
Several other issues relating to the design of the SSC-RNS were identified. First, the 
inability for the operator to rotate and deflect the ablation catheter independently of the 
sheath limits the degrees-of-freedom associated with catheter and sheath manipulation. 
Second, the loss of haptic feedback from the sheath handle prevents the EP from 
determining the sheath deflection angle in relation to its “neutral position” (i.e., when the 
sheath tip is not deflected). Finally, a digital menu system for the user interface is 
cumbersome; changing parameters and operations of the robotic system should be easily 
accessible. Future iterations of similar catheter RNS must consider these design flaws. 
4.6 Conclusion 
Commercially available robotic and magnetic catheter navigation systems have been 
demonstrated to be safe and feasible in treating cardiac arrhythmia using catheter ablation 
techniques. Although they show to reduced reduce x-ray radiation exposure and fatigue to 
the EP, they have not yet demonstrated better first-procedure success rates over the manual 
approach. For clinical uptake of new technologies entering the market, it is critical that 
they demonstrate better clinical outcomes over the manual approach. One strategy is to 
develop technologies that do not merely mimic the manual intervention, instead provide a 
level of automation such as catheter-tissue CF control. 
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In the work presented in this study, we took advantage of robotic technology to optimize 
the CF profile between the catheter tip and moving tissue. The novel RNS uses available 
force information to improve lesion production by incorporating this feature. The results 
obtained in this study suggest that the SSC-RNS can be a valuable tool available to the EP 
to not only allow or remote catheter navigation but also optimize lesion delivery techniques 
and ultimately improve first-procedure efficacy rates. 
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5 Conclusions and Future Work 
5.1 Thesis Summary 
The chapters in this thesis describe the individual steps required for the design, 
development, and evaluation of robotic technology that address problems associated with 
current cardiac catheter ablation therapy – specifically, the Catheter Contact-Force 
Controller (CFC) and Steerable Sheath and Catheter Robotic Navigation System (SSC-
RNS). These systems were evaluated in several in vitro and in vivo experiments, which 
were designed to compare robotically assisted intervention to the manual approach.  
Chapter 2 described the design, development, and in vitro evaluation of the CFC. This 
chapter also described the development and evaluation of a linear motion stage 
programmed to reproduce motion profiles corresponding to force profiles recorded during 
RF ablation in patients. The CFC was tested for its force control performance using the 
motion stage, which was fitted with a strain gauge to measure CF between the catheter tip 
and tissue-mimicking material in real-time. The control system of the CFC monitors the 
CF and processes a hybrid PID control algorithm to displace the catheter within sheath, 
thereby ensuring the set force level is always met. The CFC showed to be safe and effective 
in controlling CF. When using the CFC, the average force is within 1 g of the set level and 
variability is reduced to less than 5 (calculated as RMSE with respect to the set level) for 
each clinically appropriate force level tested (15 g, 25 g, and 40 g). In this study, the CFC 
also demonstrated to employ CF control at a set desired force level with a prescribed FTI. 
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The demonstrated control of contact force under varying motion conditions is promising 
and suggests that – when implemented in combination with a force-sensing ablation 
catheter – the CFC can deliver prescribed ablation lesions.  
The CFC was then integrated with an EAM system fitted with specialized software 
allowing real-time CF measurements, detected by a force-sensing ablation catheter, to be 
continuously streamed to the CFC electronics in real-time. System integration enabled 
additional in vitro and in vivo evaluation, described in Chapter 3. Due to the characteristics 
of the force sensor incorporated on the catheter tip (e.g., sampling time, dead-time, noise, 
et cetera), the design and implementation of two new control algorithms, replacing the 
existing hybrid PID control algorithm, were required. These algorithms were designed to 
compensate for different types of cardiorespiratory motion observed in the clinic. The force 
control performance of the CFC was first evaluated in an animal model, where a trained 
operator employed the CFC (set for 20 g) on moving targets in the RA, LA, and LV. The 
recorded CF profiles were compared to a repeat experiment whereby the operator 
attempted to maintain the desired force of 20 g using manual catheter intervention. An 
additional in vitro study was then performed to investigate CFC-assisted RF delivery to 
moving tissue, achieved by modifying the linear motion stage (described in Chapter 2) with 
a saline bath. CFC-assisted RF ablation lesions (set at different clinically relevant force 
levels) were delivered to moving tissue samples and were compared to lesions in the 
absence of motion. To compare to manual catheter intervention, a third set of RF lesions 
to moving tissue without the assistance of the CFC were delivered. For both in vivo and in 
vitro experiments, the CFC maintained an average force to within 1 g of the set level and 
significantly reduced both the contact-force variability (CFV) and relative standard of 
deviation (RSD). Specifically, in comparison to manual catheter intervention, CFC-
assisted ablation reduced the average CFV by a factor of 6.0 to less than 5 g and reduced 
the average RSD by a factor of 2.5 to less than 30%. On average, the CFC reduced the 
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standard deviation of CFV and RSD by a factor of 13.1 and 2.5, respectively. These results 
reinforce the notion that CFC-assisted ablation delivery ensures a constant CF resulting in 
more durable lesion delivery [1, 2]. Importantly, CFC-assisted ablation lesions were 
reproducible in size despite the presence of randomly selected cardiorespiratory motion. 
These lesions were statistically identical in size (depth and volume) to lesions delivered to 
tissue absent of motion, indicating precise lesion delivery. 
The CFC was then incorporated into a robotic platform enabling remote actuation of a 
steerable sheath. The novel SSC-RNS was designed to allow for full-range manipulation 
of a commercially available steerable sheath in 3-DOF (insertion, withdrawal, rotation, and 
deflection). Using the incorporated CFC, the SSC-RNS also allows for remote 
manipulation of the force-sensing ablation catheter through the sheath in 1-DOF (insertion 
and withdrawal), further enabling catheter-tissue CF control. An intuitive input device, 
designed around a repurposed steerable sheath handle fitted with embedded electronics, 
allows for wireless remote control of the robotic system. This design approach allows the 
operator to remotely navigate a catheter tip to target locations guided by an EAM system 
and employ CF control on moving targets. The SSC-RNS was first evaluated using an 
electromagnetic tracking system with sensors placed on the input unit and within the tip of 
the remote steerable sheath. This first test demonstrated sub-millimetre insertion and 
withdrawal error, a few degrees of rotational error, and negligible lag between the input 
device and robotic system of the SSC-RNS. The SSC-RNS was then evaluated in vitro 
using the linear motion stage (used in Chapter 2 and Chapter 3) modified to represent a 
beating heart phantom. Under EAM guidance, a skilled operator first navigated a remote 
catheter tip to several stationary and moving targets within the phantom. When engaging 
with moving targets, the operator employed CF control (set at 15 g) using the interface 
provided by the input device. Distances between the catheter tip and stationary target as 
well as the CF profiles generated between the catheter tip and moving targets were recorded 
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and compared to a repeated experiment using manual catheter intervention. Although 
navigational tasks took longer to complete, the catheter tip was significantly closer to the 
corresponding targets, demonstrating improved accuracy. Similar to the results obtained in 
Chapter 2 and Chapter 3, the SSC-RNS with the incorporated CFC, significantly improved 
the CF profile over manual catheter intervention. 
5.2 Contributions 
In current clinical practice, an EP would manipulate a catheter tip to a target and use the 
force information strictly as a visual guide. To the best of their abilities, the operator would 
make sure the catheter makes contact and does not exceed dangerous force levels. Whether 
or not stable CF is achieved, the EP would then deliver an RF lesion. These lesions are less 
safe, but more importantly, difficult to assess clinically – potentially increasing the risk of 
leaving reconnection gaps deep into the tissue, which may lead to early AF recurrence. As 
discussed in this thesis, the current tools and techniques available to the EP to address this 
problem is limited. 
The introduction of the CFC allows the operator to ensure that RF ablations are delivered 
safely and prescribed for each application precisely, independent of its regional location in 
the heart and extent of motion. The CFC is the first device to use the available force 
information to implement a closed-loop system to enable CF control between the catheter 
tip and moving tissue, eliminating the effects of cardiorespiratory motion on lesion 
production. The CFC is also the first device to demonstrate the ability to deliver reliably 
reproducible and precise ablation lesions in vitro. The CFC is the first tool to use robotic 
technology to optimize point-point RF lesion production. 
Clinically available robotic and magnetic navigation systems enable remote navigation of 
an ablation catheter. This design mainly provides ancillary benefits such as reduced 
fluoroscopic x-ray exposure and reduced operator fatigue. However, each of these systems 
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has its list of shortcomings that are not present in manual catheter intervention. Importantly, 
in the context of first-procedure success, none of these systems have demonstrated clear 
superiority over the manual approach. It is suspected that this is the primary reason for the 
lake of uptake of these systems into the clinic. Unless the benefits outweigh their 
shortcomings, it will be difficult for hospitals to justify purchasing and adopting these 
systems into clinical practice. Robotic systems for cardiac ablation therapy must limit their 
trade-offs and take advantage of robotic technology to improve ablation efficacy by 
implementing forms of automation. 
The SSC-RNS is a promising example of such a system. The SSC-RNS uses of 
conventional catheters and steerable sheaths permitting access to all anatomical regions of 
the heart, preserve the natural hand-eye coordination of the operator by providing an 
intuitive input device, and importantly, implements an automatic feature of closed-loop CF 
control between the catheter tip and moving cardiac tissue. To this end, the SSC-RNS is 
the only device of its kind, in the context of RF catheter ablation, that enables remote 
catheter navigation with an autonomous catheter-tissue CF control. The SSC-RNS can be 
a valuable tool available to the EP to optimize the placement and production of RF ablation 
lesions, which can ultimately lead to improved first-procedure efficacy rates. 
5.3 Future Research 
Throughout this research project, several discussions with advisors, collaborators, and 
physicians sparked ideas of further development and evaluation of the CFC and SSC-RNS. 
Proposed research projects involving both robotic systems are described in detail in the 
following sections. 
5.3.1 Fully Automated Catheter Intervention 
Implementing functional automation designed to allow for automatic movement of the 
catheter to specific targets within the cardiac chamber under EAM guidance is the future 
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direction for the SSC-RNS. The proposed added feature to the SSC-RNS would enable an 
operator to select a target within the EAM system and employ the robotic system to 
automatically guide the steerable sheath to point to the selected target and engage force 
control. The input device to the SSC-RNS would be used for fine adjustment if necessary. 
This implementation allows for fully automated catheter delivery of reliably transmural RF 
ablation lesions.  
Several robotic systems that allow for automatic catheter movements have been proposed 
and evaluated in academia. Design and evaluation of the CathROB RNS is described by 
Cercenelli et al. [3]. This system allows for remote navigation of an ablation catheter and 
implements an automatic repositioning algorithm to guide the catheter to preselected and 
memorized targets. It is assumed that this method actuates each DOF to the reference 
position previously acquired. This method is highly susceptible to external factors, 
including cardiac and patient motion, as well as a change in the position of the robot itself. 
Importantly, this method assumes the catheter is a rigid body. Due to the flexibility and 
compliance of the catheter, simply repositioning to a reference position will not reliably 
result in a tip position identical to when the reference position was acquired. Loschak et al. 
developed a more robust approach. The group developed a sophisticated 4-DOF RNS to 
manipulate intracardiac echocardiography (ICE) catheters [4, 5]. Briefly, the system uses 
an electromagnetic sensor to locate the position of the catheter tip and uses a kinematic 
model of a catheter within the control loop to robotically guide an ICE catheter along the 
pre-defined path [6, 7]. This solution enables closed-loop control of the catheter tip position 
and the ultrasound imaging plane. Other catheter kinematic models to enable automatic 
positioning of intracardiac catheters have been proposed [8, 9]. 
An automated version of the SSC-RNS would implement closed-loop control of the 
catheter tip position by developing a control system incorporating a kinematic model of 
the catheter and sheath. Since the sheath tip is (generally) not tracked by the EAM system, 
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the kinematic model must be derived while the catheter tip is in a fixed position relative to 
the sheath tip. For reliable control, this fixed position must be retained throughout 
automated navigation. 
 
Figure 5.1. Illustration of an EAM of the animal’s LA. The automated 
SSC-RNS actuates the steerable sheath (not shown) to point the tip 
towards one of six targets (white dots). The robotic system then advances 
the catheter tip (green arrow) forward and employs the force controller. 
Once an improved CF profile (green circle) is achieved, the final catheter 
tip position can be acquired (red dot). 
An in vivo study to evaluate automated SSC-RNS can be performed in a porcine model in 
a similar approach described in Chapter 3. First, an adequate electro-anatomical map of a 
pig’s LA is acquired (Figure 5.1) and registered correctly; a force-sensing ablation catheter 
can then be introduced into the cardiac chamber. The catheter and sheath can then be loaded 
into the SSC-RNS. Through the EAM, the EP can select the target location and the SSC-
RNS will automatically navigate the sheath to point towards each corresponding target. 
The force controller with then advance the catheter forward, make initial contact with the 
moving tissue, and maintain a set force level of 15 g. 
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In comparison to the manual approach, we anticipate an improved accuracy and CF profile 
using the automated SSC-RNS. Like the results obtained in Chapter 4, the catheter tip will 
be closer to the corresponding target. Additionally, similar to the results obtained in 
Chapter 2 and Chapter 3, the automated SSC-RNS will enable improved CF control and 
reduction in CF variability. The SSC-RNS will allow the operator to engage targets 
accurately and safely in a fully automated process. 
5.3.2 Further In Vivo Evaluation of CFC Impact 
To further investigate the CFC’s impact in lesion production, a series of additional in vivo 
experiments are proposed. The following section first describes a more representative 
method of performing in vivo evaluation for RF ablation experiments. This method will be 
used to investigate how the CFC can be utilized within existing lesion assessment 
techniques and emerging RF catheter technologies.  
5.3.2.1 Thigh Muscle Preparation 
In Chapter 3, the CFC was evaluated in vivo to examine its force control performance on a 
beating heart. During these experiments, RF ablation lesions were delivered to moving 
tissue with the CFC. These lesions were not quantified; instead, CFC-assisted lesion 
production was investigated in vitro to control for other factors that would have had 
unmeasurable influences on lesion production. The development of an RF-enabled 
contractile motion phantom allowed for the delivery of ablation lesions into tissue 
undergoing reproducible cardiorespiratory motion, while keeping other factors that 
influence lesion production consistent. Unfortunately, the experimental set up did not 
mimic blood and tissue temperature and did not model convective and perfusive cooling. 
Furthermore, the salinity of the water bath within the phantom was titrated to enable the 
generation of measurable lesions at the clinically relevant CF levels, RF duration, and RF 
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power. Thus, lesion production using this model does not directly reflect lesion production 
in humans.  
Typically, a thigh muscle preparation using a porcine or canine model is used in such RF 
ablation experiments [10-15]. In comparison to cardiac tissue, a thigh model is a reasonable 
technique for evaluation of ablation catheter technology [16] (Figure 5.2). In this setup, an 
incision is made within the thigh of the animal, and a thick portion of the femoris muscle 
is exposed. The skin is raised to form a chamber overlying the thigh muscle. Arterial blood 
is collected from the femoral artery, heparinized, heated to 37°C, and circulated through 
an external pump (flow rate of 200 ml/min) introduced over the exposed muscle within the 
cavity of the femoral chamber. The linear motion stage, which was used extensively and 
modified throughout this thesis, can be fitted to the leg of the animal and employ 
cardiorespiratory motion profiles, resulting in motion of the thigh muscle. A lesion 
protocol, such as the protocol described in Chapter 3, can then be performed to the thigh 
muscle; motion can be introduced by merely engaging the linear motion stage. After each 
RF application, the catheter is moved to a new position along the muscle, the femoral 
chamber is emptied, and new heated heparinized blood is introduced. The thigh muscles 
can be harvested and placed in formaldehyde and stained with 2% triphenyl tetrazolium 
chloride in phosphate-buffered saline, which is used to differentiate the necrotic tissue from 
the untreated tissue accurately. Lesion measurement and statistical analysis can follow. 
The thigh muscle preparation technique is a widely used and acceptable method for RF 
ablation experiments. Studies that adopt this experimental setup is considered to be more 
representative of lesion delivery in human. Several proposed studies, described in the 
following sections, should be performed using this technique to further evaluate the CFC 
and its effect on RF lesion production. 
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Figure 5.2. Illustration of thigh muscle preparation. Arterial blood, 
collected from the animal, is heparinized and pumped through a heat 
exchanger which is submerged in a water bath heated for 37°C. The 
blood is pumped over the femoris muscle within the chamber. A linear 
motion stage, attached to the leg of the animal, moves the femoris muscle 
resulting in cardiorespiratory motion. Illustrated was adapted from 
Leshem et al. [16]. 
5.3.2.2 Force-Time Integral Prescribed Ablation 
Force-Time Integral (FTI), defined as the area under the CF curve with respect to time 
(represented in gs), is a real-time lesion assessment tool and is commonly used during RF 
ablation therapy (Figure 5.3). In the original study that introduced this metric, performed 
by Shah et al. [17], the group demonstrates that during a 60-second RF application (at fixed 
RF power and irrigation), the highest FTI occurred when CF remained constant, which 
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resulted in the largest and deepest lesions. However, this study did not attempt to examine 
whether FTI-prescribed lesion production is dependent on CF variability. In clinical 
practice, the intended use of FTI primarily involves stopping the RF application when the 
appropriate amount of FTI is accumulated. The value is then automatically annotated 
within the EAM system at each corresponding ablation point, which can be referenced and 
evaluated throughout the procedure. Generally, the EP does not take into account CF 
variability during FTI-prescribed RF application. In other words, it is unknown whether or 
not lesion size may vary with different CF profiles (average and variability), despite 
maintaining a constant FTI. 
 
Figure 5.3. A representative example of a CF profile with 725 gs of FTI, 
indicated by the area under the CF curve with respect to time.  
One study that demonstrates the importance of CF variability in the context of FTI is the 
work done by Ullah et al. [18]. The group demonstrated that with the same FTI, the 
presence of CF variability (greater than 5 g) is associated with lower impedance drop, 
which is a surrogate for poor lesion production. This study suggests that there is a profound 
negative impact of CF variability even when FTI remains the same. The authors suggest 
that EPs should actively improve CF variability rather than delivering more FTI. Other 
than this work, there is no published data describing the role of CF variability in lesion 
5.3 Future Research 132 
 
production in the context of FTI. To this end, we propose an additional in vivo study to 
evaluate the effect of CF variability on FTI-prescribed lesion production.  
 
Figure 5.4. Representative CF profiles on moving tissue with 
approximately 600 gs FTI. A illustrates a CF profile caused by typical 
cardiorespiratory motion, B is a CF profile extracted from RF ablation 
during patient treatment, and C illustrates intermittent contact. 
 
Figure 5.5. Simulated CF profiles during CFC-assisted intervention 
when the CFC is set to deliver 600 gs FTI at 10 g, 25 g, and 40 g set force 
levels, A to C respectively. Note: achieving 600 gs FTI with low set force 
level (10 g A) requires a longer lesion duration (over 60 s), and vice-
versa (C: 40 g over 15 s). 
Using the aforementioned thigh muscle preparation, sets of ablation lesions (similarly to 
the protocol described in Chapter 3) can be delivered with and without the CFC. All RF 
applications will accumulate a total of 600 gs FTI, which can be programmed into the CFC 
to automatically retract the catheter once a set FTI is reached, Figure 2.10. Representative 
examples of 600-gs CF profiles using the manual approach and assisted by the CFC is 
illustrated in Figure 5.4 and Figure 5.5, respectively. 
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Although all lesions will be delivered with 600 gs, we suspect a variation in lesion sizes 
using the manual approach, as suggested by Ullah et al. [18]. Specifically, we anticipate a 
severe drop in lesion size in the presence of intermittent contact (Figure 5.4C). We also 
suspect that 600-gs CFC-assisted intervention will results in the reproducible lesion size, 
regardless of the presence of cardiorespiratory motion. Lastly, we hypothesize that 600-gs 
CFC-assisted lesions delivered with a higher set force will yield deeper lesions versus CFC-
assisted lesions set at a lower force.  
The results of this experiment would further demonstrate the importance of maintaining 
reduced variability in CF during RF application. Although there is an abundance of clinical 
data that suggest that CF variability is a crucial element to lesion production, there are no 
studies to date that show the importance of CF variability in lesion production in the context 
of FTI. Although FTI is a useful marker for lesion assessment, it may not tell the full story. 
5.3.2.3 Catheter Stability Under Contact-Force Control 
Maintaining spatiotemporal stability is critical for efficient transfer of RF energy into the 
tissue, resulting in a deeper, more durable RF ablation lesion. In the clinic, the stability of 
the catheter in relation to its target is affected by applied forces to the tip of the catheter, 
primarily caused by cardiorespiratory tissue motion. This results in the catheter sliding 
along the endocardium dispersing RF energy over a wider area, as illustrated in Figure 5.6. 
Increased catheter drift is associated with reduced ablation efficacy [18]. Specifically, 
catheter drift of less than 3.5 mm is associated with a higher impedance drop, even if FTI 
remains constant. A 300-gs lesion with less than 3.5 mm drift has the same impedance drop 
in comparison to a 500-gs lesion with greater than 3.5 mm drift. Furthermore, FTI levels 
greater than 400 gs did not significantly increase the impedance drop if catheter drift 
exceeded 3.5 mm. However, a stable catheter tip showed a strong correlation between 
impedance drop and FTI levels up to 900 gs. Therefore, the authors suggest that achieving 
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more efficacy lesion production is ensuring greater spatiotemporal stability, rather than just 
ablate to a higher FTI. 
 
Figure 5.6. Cardiorespiratory tissue motion (indicated in yellow) causes 
the catheter tip to slide along the surface of the endocardium (indicated 
in purple). This results in a linear but shallow ablation lesion. This effect 
may depend on the catheter-tissue incident angle, θ. 
The CFC enables CF control by adjusting the catheter within the sheath by reacting to the 
same applied external forces that cause catheter drift (cardiorespiratory motion). This 
suggests that the CFC may have an impact on catheter tip stability. In our original CFC 
studies (Chapter 2 and Chapter 3), CF control was of primary focus and catheter drift was 
not evaluated. To this end, we propose an additional in vivo study to evaluate if using the 
CFC will improve spatiotemporal stability. 
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The clinical techniques to measure catheter drift, performed by Ullah et al. [18], can be 
adopted in vivo within a thigh muscle preparation. Illustrated in Figure 5.7, a mapping 
catheter can be introduced and suspended in the blood pool within femoral chamber 
ensuring its position is not compromised by the moving tissue – this catheter will be used 
as the reference position for accurate calculation of catheter drift. Several sets of RF 
applications can be delivered to the tissue at different force levels and catheter-tissue 
incident angles. The coordinates of the tip of both ablation and mapping catheters can be 
recorded by the EAM system, which will be used to calculate the maximum relative drift. 
Statistical analysis will determine if using the CFC provides improved spatiotemporal 
stability over the manual approach and if either the set force level or incidence angle is 
significant. 
 
Figure 5.7. A secondary mapping catheter (in the form of a lasso), 
affixed to ensure it is not influenced by tissue motion (yellow), is used 
to track (green) the position of the RF electrode tip of the ablation 
catheter. The maximum catheter drift (purple) can be then determined. 
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It is hypothesized that CF control of the catheter tip will enhance spatiotemporal stability 
of the catheter tip. Therefore, the CFC-assisted ablation will likely improve spatiotemporal 
stability over the manual approach. The results from this experiment may suggest that 
CFC-assisted intervention may provide ancillary benefit in improving RF lesion 
production. 
5.3.2.4 High-Power Short-Duration Ablation 
Assessment of RF lesion production is a combination of CF, power, and duration. To this 
end, emerging RF catheter ablation techniques include delivering high-power RF energy 
(70-90 W) into the cardiac tissue for a short duration (4-8 seconds). The potential benefit 
of high-power short-duration (HPSD) ablation is to reduce the effects of lesion-to-lesion 
variability and catheter instability that cause partial-thickness lesion production. HPSD 
ablation results in improved linear continuity, shorter ablation time, and a safety profile 
comparable to conventional ablation. The less time the catheter is engaged with the tissue 
during an RF application, the less potential variability in lesion production. 
 
Figure 5.8. Overlay view of line drawings illustrating lesion geometries 
resulting from different RF lesion settings: 30 W 30 s (red), 50 W 13 s 
(purple), 60 W 10 s (green), 70 W 7 s (blue). The image was adapted 
from the original paper, published by Bourier et al. [19]. 
In comparison to standard RF ablation settings (20-35 W for 30-60 seconds), HPSD 
ablation results in similar lesion volumes but significantly different lesion geometries [19]. 
Illustrated in Figure 5.8, these lesions are generally shallower and with a larger diameter, 
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which may contribute to the better encirclement of PVs by reducing gaps between adjacent 
lesions and may suitable for PVI.  
Successful ablation using HPSD application has been shown porcine models undergoing 
PVI [20-23]. In one study, HPSD applications were delivered with 90 W for 4 seconds with 
an average CF of 14 g ± 2.6 g, while maintaining an optimal CF range between 10 g and 
20 g [20], resulting in successful ablation with no steam pops or adverse effects. In contrast, 
in a different study, HPSD ablations were delivered in swine using the same ablation 
settings and did experience steam pops [21]. In these events, HPSD applications delivered 
in the right side of the heart had an average CF between 40 g and 60 g, causing an audible 
steam pop within 3 seconds of RF application. Another group reported that achieving the 
desired CF was of prime priority and maintained CF of 10.3 ± 1.4 g [23]. Nonetheless, the 
group incurred steam pops in 11% of HPSD applications with settings of 80 W for 5 
seconds. These preclinical studies suggest implications for HPSD in treating human 
patients, primarily, that EPs would need to maintain and follow stringent CF guidelines. 
However, as discussed in detail in the Introduction section of this thesis, EPs do not have 
sufficient tools and techniques to maintain a stable CF and regularly exceed force levels 
well beyond 40 g along a 4-second window. These studies also reported a range of lesion 
depths between 1 mm and 8 mm, analyzed over hundreds of HPSD applications [21, 22]. 
Importantly the variability of lesion depths achieved in HPSD applications is comparable 
to lesions delivered using standard RF settings. In an editorial written by Patel and 
Padanilam [24], they report that large standard deviations in HPSD lesion sizes may result 
in the same problems associated with conventional ablation therapy. Specifically, each 
lesion should be sized for a particular anatomical site – meaning – shallow lesions should 
be delivered to thin tissue, and deep lesions should be delivered to thick tissue. “The search 
for the perfect burn must continue.” The results obtained in this thesis, specifically to the 
CFC, suggests that this technology may assist in HPSD ablation techniques. 
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No results have been reported, investigating CF variability in HPSD lesion production. 
However, it is evident that CF variability plays a significant role in the successful delivery 
of these lesions. To this end, we propose a final in vivo experiment to further investigate 
CF control and its impact on HPSD lesion production. Using a thigh preparation, several 
HPSD ablation sets can be delivered to moving tissue with and without the assistance of 
the CFC. Discussed in detail in the previous sections, similar ablation parameters, lesion 
measurement and analysis protocols can be followed to determine if CF variability plays a 
significant role in HPSD application and if the incorporation of the CFC provides a solution 
to ensuring reliable delivery of these lesions. 
5.3.3 Clinical Evaluation of the CFC 
The overarching goal to introduce the CFC to the clinic and perform the first-in-human 
clinical evaluation. The purpose of the first trial is to demonstrate the safety and efficacy 
of the CFC. A similar experimental protocol, outlined in Chapter 3 in vivo experiments, 
will be followed. The tip of a force-sensing ablation catheter guided with a steerable sheath 
will be navigated to targets in the RA. The CFC will then be employed at different set force 
levels typically desired for RA ablation strategies. CF profiles will be recorded and 
compared to the manual approach. In this first low-risk clinical trial, no RF applications 
will be delivered. Additional data including spatiotemporal stability will be collected to 
demonstrate the improved performance provided by the CFC.  
To evaluate the CFC in a clinical setting, an authorization to perform investigational testing 
(issued by Health Canada) is required. Acquiring approval includes demonstrating safety 
and efficacy through extensive in vitro and in vivo experimentation. The preliminary data 
collected in this thesis provides a strong foundation to aid in this application. The additional 
preclinical experiments, proposed and outlined in the previous section, will provide further 
validation demonstrating that the device is safe and effective in maintaining a stable CF 
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between the catheter tip and moving tissue. These data will help meet the regulatory 
requirements to secure authorization and bring the CFC technology to clinical evaluation. 
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B. CFC Motor Requirements: Velocity, Acceleration, and Torque 
It is critical that the motor used in the CFC can exceed peak speed and acceleration of 
endocardial tissue. An abundant amount of information relating to this subject is available 
in the literature [1-5]. Myocardial velocities have been shown – using tissue Doppler 
imaging – not to exceed 10 cm/s, with less than 1000 cm/s2. 
 
In addition to existing literature, I analyzed hundreds of contact-force profiles recorded 
during RF ablation in patients. These profiles were converted to position profiles based on 
Hooke’s law. Specifically, the force profiles were empirically scaled down until the 
systolo-diastolic displacement matches those measured in human, typically between 3-6 
mm peak-to-peak [6, 7]. The final “scaling” provided a conversion of 30 g to 1 cm. The 
derivative and second-derivatives provided velocity and acceleration profiles. A 
representative example is provided above; maximum displacement (top), velocity 
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(middle), and acceleration (bottom) are similar to the ones reported in the literature. These 
figures roughly provide maximum velocities and acceleration of tissue motion, and not 
necessarily true minimum requirements for the motor. The velocity/acceleration 
requirements for the motor should also consider the compliance of the catheter through the 
sheath (as it is not entirely rigid). The motor selected and used in this thesis has a maximum 
velocity of 230 cm/s and acceleration of 6570 cm/s2 exceeding the requirements 
determined above. 
For easy movement through the sheath, the motor must have torque capacity that 
overcomes the friction between the catheter and hemostatic seal and between the catheter 
shaft and the sheath itself. I used the setup, shown below, to measure the friction that must 
be overcome between the catheter and sheath components. 
 
In this experiment, a strain gauge was fixed to a linear carriage which glides along a rail. 
The linear position of the carriage is detected using an encoder coupled to a rack and pinion 
mechanism. The carriage was moved back and forth rapidly, and the friction and velocity 
of the carriage were recorded by a microcontroller electronics system (not shown). Data 
were recorded while the sheath was in the neutral position (not deflected) as well as 
deflected to approximately 120°, illustrated below. 
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With the sheath in the neutral position, the amount of force required to move the catheter 
through the sheath did not exceed 250 g, illustrated below. While the sheath was deflected, 
the amount of force increased to 400 g. If the sheath is fully deflected to a maximum of 
180° (not likely used in clinic), the required force can climb to 550 g. The amount of force 
required to translate the catheter through the sheath far exceeds the amount of force the 
catheter pushes onto the tissue (less 40 g). 
In the clinic, physiological 0.9% saline is introduced into the irrigation port of the steerable 
sheath to provide passive irrigation to reduce the friction between the catheter and sheath. 
The above experiment was performed with this condition as well as repeated in the absence 
of any lubrication. In dry conditions, the maximum force increased by an additional 40 g. 
This was performed to ensure that the selected motor of the CFC can withstand the highest 
friction possible. 
C. CFC Control Systems 
The CFC was integrated with a commercially available electro-anatomical catheter 
mapping system (CARTO® 3, Biosense Webster, Irvine, CA) to receive real-time force 
information from the tip of a force-sensing ablation catheter (THERMOCOOL® 
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SMARTTOUCH™, Biosense Webster, Irvine, CA). A local area network connection was 
used to establish communication between the mapping and CFC systems. Significant 
degradation in the measurement of real-time CF (i.e. slow 20 Hz sampling rate, long time-
delay, noise, et cetera) was discovered. Because of this, two control systems were 
developed to provide compensation for a wide variety of variations in CF caused by cardiac 
and respiratory tissue motion, or patient and catheter motion.  
The following sections briefly describe two control systems used in the CFC system. The 
adaptive and repetitive control systems were first implemented in MATLAB Simulink 
(Mathworks, Natick, MA) and their response to changes in CF was evaluated in a simulated 
environment. I implemented both control systems in the electronic hardware of the CFC as 
software code processed on an ARM-based microcontroller (Arduino Due, Arduino, Turin, 
Italy). 
Adaptive Control System 
The model reference adaptive control (MRAC) system is a direct adaptive strategy that 
uses an adjustment mechanism to adjust the response of the controller [8]. In comparison 
to standard simple-structured fixed-gain controllers, such as the proportional-integral-
derivative (PID) controllers, adaptive controllers are very useful in handling the unknown 
variations in parameters and environmental changes (e.g. change in catheter angle, tissue 
compliance, deflection of sheath tip).  
The MRAC, illustrated in the block diagram below, consists of two loops, a standard 
feedback loop and parameter adjustment loop. The adjustment mechanism uses the 
constant gain to reduce the cost function to zero in an iterative process. This strategy works 
on the principle of adjusting the controller parameters so that the output of the system plant 
(measured force), P(s), tracks the output of a reference model, R(s), having the same 
reference input (desired force). The reference input is first filtered by a low-pass filter, S(s). 
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An adjustment mechanism uses a learning rate, γ, to reduce the cost function to zero. The 
controller, C(s), takes the form of a standard integral (I) controller and generates a control 
signal which is sent to the linear motor of the force controller. All models were 
implemented as discrete-time transfer functions as software code on the microcontroller-
based electronic system of the CFC. 
 
Through simulation, the MRAC was found to be an adequate controller to compensate for 
gradual disturbances in CF changes, such as those caused by respiration, patient and 
catheter motion. Additionally, this strategy is stable and does not increase the amplitude of 
higher frequency components (i.e. cardiac motion); a common problem associated with 
poorly sampled feedback closed-loop systems using standard PID controllers. The MRAC 
strategy provides no attempt to compensate for changes in cardiac motion. 
Repetitive Control System 
To compensate for substantial variation in CF caused by the systolo-diastolic motion of the 
heart, a repetitive control strategy was also implemented. The repetitive strategy is based 
on a Smith predictor, which is a predictive controller commonly used for systems with 
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significant time delay in the control loop [9, 10]. A Smith predictor is an appropriate 
solution for processes that have a dead-time (or time-delay) longer than the time constant, 
making it suitable for our force-control application, where the time constant is small 
(measured to be less than 35 ms).  
A standard Smith predictor alone cannot compensate for large rapid fluctuations in CF. To 
address this, the standard Smith predictor was modified to enable repetitive control 
designed to reject periodic disturbances [11]. Illustrated in the block diagram below, the 
modified Smith predictor uses an added block to further delay the control loop by an 
appropriate amount in order to synchronize the feedback loop with the periodic 
disturbance. The known heart rate and modelled time-delay in the force sensor of the force-
sensing ablation catheter are used to determine the additional delay required; this also can 
be used to eliminate CF variation caused by respiration. In the current implementation, the 
operator dials-in the desired frequency in beats per minute to eliminate CF fluctuations 
caused by cardiac motion, or, breaths-per-minute to eliminate respiratory motion. 
 
The modified Smith predictor, illustrated above, generates a control signal to the linear 
motor based on the controller, C(s), which takes the form of a proportional-integral (PI) 
controller. This is based on the difference between the feedback measured force signal and 
the desired force, which is filtered by a low-pass filtered, S(s). A delay-less model of the 
plant, Pm(s), is a second-order transfer function modelling the real system plant, P(s), to 
predict the force measurement ahead of time. The force sensor delay is estimated, and the 
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amount of extra delay (shown in red) needed to synchronize the force controller with 
periodic disturbance (cardiac or respiratory) is calculated by subtracting the estimated 
delay from the period of the disturbance. All models were implemented as discrete-time 
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E. Comparison of Force Control: In Vitro to Simulation 
The block diagram of the repetitive control loop illustrated in Appendix C (Repetitive 
Control System) was implemented in MATLAB Simulink (Mathworks, Natick, MA) to 
simulate the force control response of the SSC-RNS. A representative example comparing 
a robotically assisted force control experiment performed in vitro with its simulation is 
illustrated below. 
 
The SSC-RNS employed force control on the 17.5-second mark. For this example, the 
linear motion stage of the phantom was set to execute cardiac motion at 80 BPM and 
respiratory motion at 20 BPM with a 3:8 amplitude ratio. The motion was prescribed as the 
disturbance profile within the block diagram of the control loop (Appendix C, Repetitive 
Control System, added to the output of the plant, P(s)). To compensate for the dominant 
respiratory component, the SSC-RNS was set to respiratory gating, which synchronized 
the controller by further delaying the control loop by approximately one respiratory cycles 
period (20 BPM or 3 seconds). Respiratory gating was simulated by setting the extra delay 
with the control loop (Appendix C, Repetitive Control System, extra delay block in red) to 
the same amount. The measured CF profile and its simulated response demonstrated 
complete elimination of the large swings in force caused by respiration. In comparison to 
the simulation, the measured response demonstrated a slightly better CF control 




[1] L. Thomas, K. Levett, A. Boyd, D. Y. Leung, N. B. Schiller, and D. L. Ross, 
"Changes in regional left atrial function with aging: evaluation by Doppler tissue 
imaging," Eur J Echocardiogr, vol. 4, no. 2, pp. 92-100, 2003 
[2] M. Duytschaever et al., "Transthoracic tissue Doppler imaging of the atria: a novel 
method to determine the atrial fibrillation cycle length," J Cardiovasc 
Electrophysiol, vol. 17, no. 11, pp. 1202-9, 2006 
[3] I. Limantoro et al., "Clinical correlates of echocardiographic tissue velocity 
imaging abnormalities of the left atrial wall during atrial fibrillation," Europace, 
vol. 16, no. 11, pp. 1546-53, 2014 
[4] N. Yoshida, M. Okamoto, and T. Fukuhara, "Left atrial wall motion velocity 
measured by the velocity profile method with tissue Doppler echocardiography in 
normal subjects: its relation to aging," J Med Ultrason (2001), vol. 31, no. 3, pp. 
103-9, 2004 
[5] K. Mori, Y. Hayabuchi, Y. Kuroda, M. Nii, and T. Manabe, "Left ventricular wall 
motion velocities in healthy children measured by pulsed wave Doppler tissue 
echocardiography: normal values and relation to age and heart rate," J Am Soc 
Echocardiogr, vol. 13, no. 11, pp. 1002-11, 2000 
[6] H. Skulstad et al., "Grading of myocardial dysfunction by tissue Doppler 
echocardiography: a comparison between velocity, displacement, and strain 
imaging in acute ischemia," J Am Coll Cardiol, vol. 47, no. 8, pp. 1672-82, 2006 
[7] A. Manouras et al., "Are measurements of systolic myocardial velocities and 
displacement with colour and spectral Tissue Doppler compatible?," Cardiovasc 
Ultrasound, vol. 7, p. 29, 2009 
[8] P. Jain and M. J. Nigam, "Design of a Model Reference Adaptive Controller Using 
Modifited MIT Rule for a Second Order System," Advance in Electronic and 
Electric Engineering, vol. 3, no. 4, pp. 477-484, 2013 
[9] O. J. M. Smith, "Closed Control of Loops with Dead Time," Chemical Engineering 
Process, 1957 
[10] A. Ingimundarson and T. Hägglund, "Robust tuning procedures of dead-time 
compensating controllers," Control Engineering Practice, vol. 9, no. 11, pp. 1195-
1208, 2001 
[11] W. Qing-Guo, Z. Han-Qin, Y. Yong-Sheng, Z. Yong, and Z. Yu, "Modified Smith 
predictor design for periodic disturbance rejection," in Asian Control Conference, 
2004, vol. 2: IEEE, pp. 1145-50. 
  
Curriculum Vitae 
DANIEL GELMAN, PH.D 
 
Robarts Research Institute 
University of Western Ontario 
1151 Richmond St. North 





Doctor of Philosophy Candidate, School of Biomedical Engineering 
University of Western Ontario, London, ON, Canada 
Supervisor: Maria Drangova, Ph.D. 





Bachelor of Engineering, Electrical and Biomedical Engineering 
McMaster University, Hamilton, ON, Canada 
Supervisor: Hubert de Bruin, Ph.D., P.Eng. 




Aufero Medical Technologies, Inc. 









Mechatronic Systems Engineer 




Instrumentation Control Systems Engineer 
Brockhouse Institute for Materials Research 
155 Curriculum Vitae 
 
PUBLICATIONS & CONFERENCES 
Refereed Journal Manuscripts 
1. Gelman D, Skanes AC, Drangova M, "Remote Catheter Navigation and Contact-
Force Control: Design and Evaluation of a Novel Steerable Sheath and Catheter 
Robotic Navigation System," IEEE Trans Biomed Eng, 2019. (In Preparation) 
2. Gelman D, Skanes AC, Jones DL, Timofeyev M, Baron T, Drangova M, 
"Eliminating the Effects of Motion during Radiofrequency Lesion Delivery using 
a Novel Contact-Force Controller," J Cardiovasc Electrophysiol, 2019. (Accepted) 
3. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a 
Catheter Contact-Force Controller for Cardiac Ablation Therapy," IEEE Trans 
Biomed Eng, vol. 63, no. 11, pp. 2301-7, 2016. 
4. Tavallaei MA, Gelman D, Lavdas MK, Skanes AC, Jones DL, Bax JS, Drangova 
M, "Design, development and evaluation of a compact telerobotic catheter 
navigation system," Int J Med Robot, vol. 12, no. 3, pp. 442-52, 2015. 
5. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "Magnetic resonance 
imaging compatible remote catheter navigation system with 3 degrees of freedom", 
Int J Comput Assist Radiol Surg, vol. 11, no. 8, pp. 1537-45, 2015. 
Peer-Reviewed Published Conference Abstracts 
1. Gelman D, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," Cardiac Arrhythmia 
Network of Canada, Halifax, NS, Canada, 2017. 
2. Gelman D, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," Imaging Network of 
Ontario, London, ON, Canada, 2017.  
3. Gelman D, Skanes AC, Jones DL, Drangova M, " Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," London Health Research 
Day, London, ON, Canada, 2017.  
4. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "MRI-Compatible Remote 
Catheter Navigation System", iMRI 2016, Baltimore, MD, USA, 2016. 
5. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Heart Rhythm, San 
Fransico, CA, USA, 2016.  
6. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a 
Catheter Contact-Force Controller for Cardiac Ablation Therapy," Imaging 
Network of Ontario, Toronto, ON, Canada, 2016.  
7. Tavallaei MA, Lavdas MK, Gelman D, Drangova M, "MRI-Compatible Remote 
Catheter Navigation System with 3-Degrees-of-Freedom", Imaging Network of 
Ontario, Toronto, ON, Canada, 2016.  
Curriculum Vitae 156 
 
8. Gelman D, Skanes AC, Tavallaei MA, Drangova M, "Design and Evaluation of a 
Catheter Contact-Force Controller for Cardiac Ablation Therapy," London Health 
Research Day, London, ON, Canada, 2016.  
9. Gelman D, Lavdas MK, Drangova M, "Real-Time Three Degree-of-Freedom 
Measurement of Catheter Motion for Input to a Robotic Catheter Navigation 
System," IUPESM: World Congress of Medical Physics and Biomedical 
Engineering, Toronto, ON, Canada, 2015.  
10. Gelman D, Lavdas MK, Drangova M, "An Instinctive 3-Degree-of-Freedom 
Master-Side Input Device to a Robotic Catheter Navigation System", Imaging 
Network of Ontario, London, ON, Canada, 2015.  
11. Tavallaei MA, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M, 
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation 
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON, 
Canada, 2015.  
12. Gelman D, Tavallaei MA, Drangova M, "Towards Semi-Autonomous Remote 
Cardiac Catheter Navigation," London Health Research Day, London, ON, 
Canada, 2014. 
Peer-Reviewed Oral Presentations (*presenting author) 
1. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control 
for Cardiac Ablation Therapy," Society of Cardiac Robotic Navigation, Chicago, 
IL, USA, 2017.  
2. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," Imaging Network of 
Ontario, London, ON, Canada, 2017.  
3. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Cardiac 
Arrhythmia Network of Canada, Calgary, AB, Canada, 2016.  
4. Tavallaei MA, Lavdas MK, Gelman D*, Drangova M, "MRI-Compatible Remote 
Catheter Navigation System with 3-Degrees-of-Freedom", Imaging Network of 
Ontario, Toronto, ON, Canada, 2016.  
5. Gelman D*, Lavdas MK, Drangova M, "Real-Time Three Degree-of-Freedom 
Measurement of Catheter Motion for Input to a Robotic Catheter Navigation 
System," IUPESM: World Congress of Medical Physics and Biomedical 
Engineering, Toronto, ON, Canada, 2015.  
6. Tavallaei MA*, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M, 
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation 
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON, 
Canada, 2015.  
157 Curriculum Vitae 
 
Peer-Reviewed Poster Presentations (*presenting author) 
1. Gelman D*, Skanes AC, Jones DL, Drangova M, "Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," Cardiac Arrhythmia 
Network of Canada, Halifax, NS, Canada, 2017. 
2. Gelman D*, Skanes AC, Jones DL, Drangova M, " Catheter Contact-Force Control 
during Cardiac Ablation Therapy: In Vivo Evaluation," London Health Research 
Day, London, ON, Canada, 2017.  
3. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Cardiac 
Arrhythmia Network of Canada, Calgary, AB, Canada, 2016. 
4. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Heart Rhythm, San 
Francisco, CA, USA, 2016. 
5. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," Imaging Network 
of Ontario, Toronto, ON, Canada, 2016. 
6. Gelman D*, Skanes AC, Tavallaei MA, Drangova M, "Catheter Contact-Force 
Control during Cardiac Ablation Therapy: In Vitro Evaluation," London Health 
Research Day, London, ON, Canada, 2016. 
7. Gelman D*, Lavdas MK, Drangova M, "An Instinctive 3-Degree-of-Freedom 
Master-Side Input Device to a Robotic Catheter Navigation System", Imaging 
Network of Ontario, London, ON, Canada, 2015. 
8. Tavallaei MA*, Gelman D, Lavdas MK, Skanes AC, Jones DL, Drangova M, 
"Design, Development and in vivo Evaluation of a Remote Catheter Navigation 
System with 3-Degrees-of-Freedom", Imaging Network of Ontario, Toronto, ON, 
Canada, 2015. 
9. Gelman D*, Tavallaei MA, Drangova M, "Towards Semi-Autonomous Remote 
Cardiac Catheter Navigation," London Health Research Day, London, ON, 
Canada, 2014. 
GRADUATE TEACHING ASSISTANTSHIP 
University of Western Ontario, London, ON, Canada 
Introduction to Electrical Instrumentation (MSE2201) 
Mechatronics Engineering 
 
Electrical Circuits and Electromechanics (ECE2274) 
Electrical and Computer Engineering 
 
Introduction to Medical Imaging (BME9513) 
Biomedical Engineering  
 
Curriculum Vitae 158 
 
Introduction to Electronics for Mechanical Engineering (ECE3374) 
Electrical and Computer Engineering 
 
Programming Fundamentals for Engineers (ES1036) 
Engineering Science 
 
Introductory Engineering Design and Innovation Studio (ES1050)  
Engineering Science  
GRANTS 
Feb. 2018 
Commercialization Grant – $300,000 
Cardiac Arrhythmia Network of Canada (CANet), Co-Applicant  
Funds provided to accelerate the development of promising inventions originating from 
the university sector to promote their transfer into the Canadian healthcare environment. 
The Commercialization Grant provides funding to CANet Network Investigators and 
CHAT Members to support research and development projects with recognized 
technology transfer potential. 
  
Mar. 2017 
BURST – $70,000  
TechAlliance, Awarded to Aufero Medical 
Incubation program for high-potential medical technology start-ups intended to 
position London as a focal point for life science innovation. 
  
Sept. 2016 
CHAT Discovery Award – $25,000 
Cardiac Arrhythmia Network of Canada 
This award supported novel research ideas from CHAT (CANet HQP Association for 
Trainees) members. Funds were granted to the trainees to initiate their proposed research 
project under the supervision/mentoring of a CANet Network Investigator (Dr. 




Entrepreneurship-Accelerate Postdoctoral Fellowship – $110,000 




Ontario Graduate Scholarship – $15,000 




NSERC CREATE: CAMI – $24,000 
University of Western Ontario 
COMMITTEES & VOLUNTEER ACTIVITIES 
Aug. 2017 
Mar. 2018 
2017/18 Proteus Innovation Competition 
Aufero Medical 




CHAT Executive Committee 
Cardiac Arrhythmia Network of Canada 
Currently organizing and chairing a session on Pathway to Commercialization at 2019 
CANet Annual Scientific Meeting. 
  
159 Curriculum Vitae 
 
Feb. 2015 
Recruitment Event: Robotic Catheter Systems  





University of Western Ontario, School of Biomedical Engineering 
PATENTS 
July 2018 
Catheter Contact-Force Control Device 






















Aufero Medical Technologies, Inc. 
Incorporation 
 
